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Abstract
Improving Risk Factor Identification of Human Complex Traits in Omics Data
Weimiao Wu
2021

With recent advances in various high throughput technologies, the rise of omics data
offers a promise of personalized health care with its potential to expand both the depth
and the width of the identification of risk factors that are associated with human complex
traits. In genomics, the introduction of repeated measures and the increased sequencing
depth provides an opportunity for deeper investigation of disease dynamics for patients.
In transcriptomics, high throughput single-cell assays provide cellular level gene
expression depicting cell-to-cell heterogeneity. The cell-level resolution of gene
expression data brought the opportunities to promote our understanding of cell function,
disease pathogenesis, and treatment response for more precise therapeutic development.
Along with these advances are the challenges posed by the increasingly complicated data
sets. In genomics, as repeated measures of phenotypes are crucial for understanding the
onset of disease and its temporal pattern, longitudinal designs of omics data and
phenotypes are being increasingly introduced. However, current statistical tests for
longitudinal outcomes, especially for binary outcomes, depend heavily on the correct
specification of the phenotype model. As many diseases are rare, efficient designs are
commonly applied in epidemiological studies to recruit more cases. Despite the enhanced
efficiency in the study sample, this non-random ascertainment sampling can be a major
source of model misspecification that may lead to inflated type I error and/or power loss
1

in the association analysis. In transcriptomics, the analysis of single-cell RNA-seq data is
facing its particular challenges due to low library size, high noise level, and prevalent
dropout events. The purpose of this dissertation is to provide the methodological
foundation to tackle the aforementioned challenges. We first propose a set of
retrospective association tests for the identification of genetic loci associated with
longitudinal binary traits. These tests are robust to different types of phenotype model
misspecification and ascertainment sampling design which is common in longitudinal
cohorts. We then extend these retrospective tests to variant-set tests for genetic rare
variants that have low detection power by incorporating the variance component test and
burden test into the retrospective test framework. Finally, we present a novel gene-graph
based imputation method to impute dropout events in single-cell transcriptomic data to
recover true gene expression level by borrowing information from adjacent genes in the
gene graph.
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Chapter 1

Single-SNP Retrospective Association Tests
For Longitudinal Binary Traits
1.1 Abstract
Longitudinal phenotypes have been increasingly available in genome-wide
association studies (GWAS) and electronic health record-based studies for identification
of genetic variants that influence complex traits over time. For longitudinal binary data,
there remain significant challenges in gene mapping, including misspecification of the
model for the phenotype distribution due to ascertainment. Here, we propose L-BRAT, a
retrospective, generalized estimating equations-based method for genetic association
analysis of longitudinal binary outcomes. We also develop RGMMAT, a retrospective,
generalized linear mixed model-based association test. Both tests are retrospective score
approaches in which genotypes are treated as random conditional on phenotype and
covariates. They allow both static and time-varying covariates to be included in the
analysis. Through simulations, we illustrated that retrospective association tests are
robust to ascertainment and other types of phenotype model misspecification, and gain
power over previous association methods. We applied L-BRAT and RGMMAT to a
genome-wide association analysis of repeated measures of cocaine use in a longitudinal
cohort. Pathway analysis implicated association with opioid signaling and axonal
guidance signaling pathways. Lastly, we replicated important pathways in an independent
14

cocaine dependence case-control GWAS. Our results illustrate that L-BRAT is able to
detect important loci and pathways in a genome scan and to provide insights into genetic
architecture of cocaine use.

1.2 Introduction
Genome-wide association studies (GWAS) have successfully discovered many
disease susceptibility loci and provided insights into the genetic architecture of numerous
human complex diseases and traits. In some genetic epidemiological studies,
longitudinally collected phenotype data are available. This is the case for many electronic
health record (EHR)-based studies. As many of these studies continue to follow enrolled
subjects (e.g. the UK Biobank (UKB) and the Million Veteran Program (MVP)),
longitudinal phenotypes will be increasingly available with the passage of time, providing
new data resources that require appropriate analytical tools for optimal analysis. Standard
association tests that consider one time point or collapse repeated measurements into a
single value such as an average do not capture the trajectory of phenotypic traits over
time and may result in a loss of statistical power to detect genetic associations. In
addition, the effects of time-varying covariates cannot be easily incorporated in such
analyses. Recently, methodological developments for GWAS have proliferated to make
full use of the available longitudinal data. For population cohorts, methods that account
for dependence among observations from an individual include mixed effects models
[1,2], generalized estimating equations (GEE) [3], growth mixture models[4,5], and
empirical Bayes models [6]. Most of these approaches are prospective analyses and have
been successfully applied to quantitative phenotypes.
15

As many diseases are rare, efficient designs, such as the case-control design, are
commonly applied in epidemiological studies to recruit study subjects. Despite the
enhanced efficiency in the study sample, non-random ascertainment can be a major
source of model misspecification that may lead to inflated type I error and/or power loss
in association analysis. The linear mixed model and the logistic mixed model do not
perform well when the case-control ratio is unbalanced in large-scale genetic association
studies [7]. Prospective analysis in which a population-based model is used ignores
ascertainment bias and can result in compromised statistical inference. Furthermore, in
the ascertained sample, the prospective approach conditional on the genotype and
covariates may lose information when the joint distribution of the genotype and
covariates carries additional information on whether the phenotype is associated with the
genotype [8]. In this regard, several retrospective association methods have been
proposed for analyzing ascertained population-based case-control studies [9,10], familybased studies of continuous traits [11], family-based case-control studies [12,13], and
family-based longitudinal quantitative traits [14]. Compared to prospective tests,
retrospective tests conditional on the phenotype and covariates are more robust to
misspecification of the trait model[8].
To generalize case-control sampling, outcome-dependent sampling designs have
become popular for binary data in longitudinal cohort studies [15–17]. However,
association tests for longitudinally measured binary data are less well developed in
GWAS. Here, we propose L-BRAT, a retrospective, GEE-based method for genetic
association analysis of longitudinal binary outcomes. It requires specification of the mean
of the outcome distribution and a working correlation matrix for repeated measurements.
16

L-BRAT is a retrospective score approach in which genotypes are treated as random
conditional on the phenotype and covariates. Thus, it is robust to ascertainment and trait
model misspecification. It allows both static and time-varying covariates to be included
in the analysis. We note that GMMAT, a recently proposed prospective test using the
logistic mixed model to control for population structure and cryptic relatedness in casecontrol studies [18], can be adapted for repeated binary data. For comparison, we also
develop RGMMAT, a retrospective, generalized linear mixed model (GLMM)-based
association test for longitudinal binary traits.
We performed simulation studies to evaluate the type I error and power of L-BRAT
and RGMMAT, and compared them to the existing prospective methods. The results
demonstrate that the retrospective association tests have better control of type I error
when the phenotype model is misspecified, and are robust to various ascertainment
schemes. Moreover, they are more powerful than the prospective tests. Finally, we
applied L-BRAT and RGMMAT to a genome-wide association analysis of repeated
measurements of cocaine use in a longitudinal cohort, the Veterans Aging Cohort Study
(VACS), and replicated the results using data from an independent cocaine dependence
case-control GWAS.

1.3 Materials and methods
Suppose a binary trait is measured over time on a study population of 𝑛𝑛 individuals.

We have their genome-wide measures of genetic variation. A set of covariates, static or
dynamic, are also available. Let 𝑛𝑛𝑖𝑖 be the number of repeated measures on individual 𝑖𝑖
17

and 𝑁𝑁 = ∑𝑛𝑛𝑖𝑖=1 𝑛𝑛𝑖𝑖 be the total number of observations. For individual 𝑖𝑖, let 𝑿𝑿𝑖𝑖𝑖𝑖 and 𝑌𝑌𝑖𝑖𝑖𝑖 be
the 𝑝𝑝-dimensional covariate vector, assumed to include an intercept, and the binary
response at time 𝑡𝑡𝑖𝑖𝑖𝑖 , respectively. In this setting, individuals are permitted to have

measurements at different time points and different number of observations. We let 𝒀𝒀
denote the outcome vector of length 𝑁𝑁, and let 𝑿𝑿 denote the 𝑁𝑁 × 𝑝𝑝 covariate matrix.

Here, we focus on the problem of testing for association between a genetic variant and
the longitudinal binary outcomes. Let 𝑮𝑮 denote the vector of genotypes for the 𝑛𝑛

individuals at the variant to be tested, where 𝐺𝐺𝑖𝑖 = 0, 1, or 2 is the number of minor alleles
of individual 𝑖𝑖 at the variant.
1.3.1

Generalized estimating equations (GEE) model

We consider a GEE approach in which the mean of the outcome distribution, given
the genotype and covariates, is specified as
𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮, 𝑿𝑿� = 𝜇𝜇𝑖𝑖𝑖𝑖 , logit �𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜷𝜷 + 𝐺𝐺𝑖𝑖 𝛾𝛾, 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 ,

(1)

where 𝜷𝜷 is a 𝑝𝑝-dimensional vector of covariate effects and 𝛾𝛾 is a scalar parameter of

interest representing the effect of the tested variant. Writing in a matrix form, we have the
mean model
𝐸𝐸(𝒀𝒀 | 𝑮𝑮, 𝑿𝑿) = 𝝁𝝁, logit (𝝁𝝁) = 𝑿𝑿𝑿𝑿 + 𝑩𝑩𝑩𝑩𝛾𝛾,

(2)

where 𝑩𝑩 is an 𝑁𝑁 × 𝑛𝑛 matrix representing the measurement clustering structure, and its

(𝑙𝑙, 𝑖𝑖)th entry 𝐵𝐵𝑙𝑙𝑙𝑙 is an indicator of the 𝑙𝑙th entry of 𝒀𝒀 being a measurement on individual 𝑖𝑖.
Here, the vector 𝑩𝑩𝑩𝑩 is the vertically expanded genotype vector that maps the genotype

data 𝑮𝑮 from the individual level to the measurement level. The covariance structure of 𝒀𝒀

is given by
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(3)

Var(𝒀𝒀 | 𝑮𝑮, 𝑿𝑿) = 𝚪𝚪1/2 𝚺𝚺𝚪𝚪1/2 ,

where 𝚪𝚪 = diag�𝜇𝜇1,1 �1 − 𝜇𝜇1,1 �, … , 𝜇𝜇1,𝑛𝑛1 �1 − 𝜇𝜇1,𝑛𝑛1 �, … , 𝜇𝜇𝑛𝑛,1 �1 − 𝜇𝜇𝑛𝑛,1 �, … , 𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛 �1 −

𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛 �� is an 𝑁𝑁-dimensional diagonal matrix and 𝚺𝚺 is an 𝑁𝑁 × 𝑁𝑁 correlation matrix. The

covariance specification in Eq. (3) ensures that the variance of the dichotomous response
𝑌𝑌𝑖𝑖𝑖𝑖 depends on its mean in a way that is consistent with the Bernoulli distribution. To
apply the GEE method, a working correlation structure such as independent,

exchangeable, and first-order autoregressive (AR(1)) must be specified. For a given
within-cluster correlation matrix 𝚺𝚺(𝜏𝜏), which may depend on some parameter 𝜏𝜏, the
estimating equations for the unknown parameters (𝜷𝜷, 𝛾𝛾) are written as
𝑼𝑼 = �

𝑼𝑼(𝜷𝜷)
𝑿𝑿𝑇𝑇 𝚪𝚪1/2 𝚺𝚺 −1 𝚪𝚪 −1/2 (𝒀𝒀 − 𝝁𝝁)
�=�
�.
𝑈𝑈(𝛾𝛾)
(𝑩𝑩𝑩𝑩)𝑇𝑇 𝚪𝚪1/2 𝚺𝚺 −1 𝚪𝚪 −1/2 (𝒀𝒀 − 𝝁𝝁)

To detect association between the genetic variant and the phenotype, we consider a
score approach to test 𝐻𝐻0 : 𝛾𝛾 = 0 against 𝐻𝐻1 : 𝛾𝛾 ≠ 0. The null estimate of 𝜷𝜷, denoted by

� 0 , is the solution to a system of estimating equations 𝑼𝑼(𝜷𝜷) = 0 under the constraint 𝛾𝛾 =
𝜷𝜷

0, which can be computed iteratively between a Fisher scoring algorithm for 𝜷𝜷 and the
method of moments for 𝜏𝜏 until convergence. Then, the score function for 𝛾𝛾 is
1/2 � −1 � −1/2
(𝒀𝒀 − 𝝁𝝁
� 0 ),
𝑈𝑈0 = 𝑈𝑈(𝛾𝛾)|𝜷𝜷�0 ,0,𝜏𝜏�0 = (𝑩𝑩𝑩𝑩)𝑇𝑇 𝚪𝚪�0 𝚺𝚺
0 𝚪𝚪0

(4)

� 0 , 0, 𝜏𝜏̂ 0 �.
�0 are 𝝁𝝁, 𝚪𝚪 and 𝚺𝚺 evaluated at (𝜷𝜷, 𝛾𝛾, 𝜏𝜏) = �𝜷𝜷
� 0 , 𝚪𝚪�0 and 𝚺𝚺
where 𝝁𝝁

In the GEE approach, the prospective score statistic for testing 𝐻𝐻0 : 𝛾𝛾 = 0 takes the

form

𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺 =

𝑈𝑈02

Var0 �𝑈𝑈0 �

𝑮𝑮, 𝑿𝑿�

=

2
1/2 � −1 � −1/2
(𝒀𝒀−𝝁𝝁
� 0 )�
𝚺𝚺0 𝚪𝚪0
(𝑩𝑩𝑩𝑩)𝑇𝑇 𝑸𝑸𝑸𝑸𝑸𝑸

�(𝑩𝑩𝑩𝑩)𝑇𝑇 𝚪𝚪�0
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,

(5)

where the null variance of 𝑈𝑈0 is evaluated using a robust sandwich variance estimator,

conditional on the genotype and covariates. Here 𝑸𝑸 = 𝑽𝑽 − 𝑽𝑽𝑽𝑽(𝑿𝑿𝑇𝑇 𝑽𝑽𝑽𝑽)−1 𝑿𝑿𝑇𝑇 𝑽𝑽, where

1/2 � −1 � −1/2 �
−1/2 � −1 � 1/2
� (𝒀𝒀), is
𝑽𝑽 = 𝚪𝚪�0 𝚺𝚺
Cov(𝒀𝒀)𝚪𝚪�0 𝚺𝚺
and the sample covariance of 𝒀𝒀, Cov
0 𝚪𝚪0
0 𝚪𝚪0

� 0 )(𝒀𝒀 − 𝝁𝝁
� 0 )𝑇𝑇 . Under the null hypothesis, the 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺 test statistic has an
estimated by (𝒀𝒀 − 𝝁𝝁
asymptotic 𝜒𝜒12 distribution.
1.3.2

L-BRAT retrospective test

In what follows, we introduce a new GEE-based association testing method, L-BRAT
(Longitudinal Binary-trait Retrospective Association Test). The L-BRAT test statistic is
also based on the score function 𝑈𝑈0 in Eq. (4). In contrast to the prospective GEE score
test, L-BRAT takes a retrospective approach in which the variance of 𝑈𝑈0 is assessed
using a retrospective model of the genotype given the phenotype and covariates. An
advantage of the retrospective approach is that the analysis is less dependent on the
correct specification of the phenotype model. We assume that under the null hypothesis
of no association between the genetic variant and the phenotype, the quasi-likelihood
model of 𝑮𝑮 conditional on 𝒀𝒀 and 𝑿𝑿 is

𝐸𝐸0 (𝑮𝑮 | 𝒀𝒀, 𝑿𝑿) = 2𝑝𝑝𝟏𝟏𝑛𝑛 , Var0 (𝑮𝑮 | 𝒀𝒀, 𝑿𝑿) = 𝜎𝜎𝑔𝑔2 𝚽𝚽,

where 𝑝𝑝 is the minor allele frequency (MAF) of the tested variant, 𝟏𝟏𝑛𝑛 is a vector of

(6)

length 𝑛𝑛 with every element equal to 1, 𝜎𝜎𝑔𝑔2 is an unknown variance parameter, and 𝚽𝚽 is
an 𝑛𝑛 × 𝑛𝑛 genetic relationship matrix (GRM) representing the overall genetic similarity

between individuals due to population structure. Because 𝑩𝑩𝟏𝟏𝑛𝑛 = 𝟏𝟏𝑁𝑁 , which is the first

1/2 � −1 � −1/2
(𝒀𝒀 − 𝝁𝝁
� 0 ), the 𝑁𝑁-dimensional
column of 𝑿𝑿 that encodes an intercept, and 𝚪𝚪�0 𝚺𝚺
0 𝚪𝚪0
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vector of transformed null phenotypic residuals, is orthogonal to the column space of 𝑿𝑿,
then the null mean model of 𝑮𝑮 in Eq. (6) ensures that

𝐸𝐸0 (𝑈𝑈0 | 𝒀𝒀, 𝑿𝑿) = 𝐸𝐸0 (𝑨𝑨𝑇𝑇 𝑮𝑮 | 𝒀𝒀, 𝑿𝑿) = 2𝑝𝑝𝑨𝑨𝑇𝑇 𝟏𝟏𝑛𝑛 = 0,

1/2 � −1 � −1/2
(𝒀𝒀 − 𝝁𝝁
� 0 ) is the individual-level transformed phenotypic
where 𝑨𝑨 = 𝑩𝑩𝑇𝑇 𝚪𝚪�0 𝚺𝚺
0 𝚪𝚪0

residual vector of length 𝑛𝑛.

In model (6), the GRM 𝚽𝚽 can be obtained using genome-wide data, given by
𝐾𝐾

𝑇𝑇

�𝑮𝑮(𝑘𝑘) − 2𝑝𝑝̂𝑘𝑘 ��𝑮𝑮(𝑘𝑘) − 2𝑝𝑝̂ 𝑘𝑘 �
1
𝚽𝚽 = �
,
𝐾𝐾
2𝑝𝑝̂ 𝑘𝑘 (1 − 𝑝𝑝̂ 𝑘𝑘 )
𝑘𝑘=1

where 𝐾𝐾 is the total number of genotyped variants, 𝑮𝑮(𝑘𝑘) is the genotype vector at the 𝑘𝑘th

variant, and 𝑝𝑝̂ 𝑘𝑘 is the estimated MAF, for example, 𝑝𝑝̂ 𝑘𝑘 = 𝐺𝐺̅𝑘𝑘 /2, the sample MAF at the
𝑘𝑘th variant. For the variant of interest, let 𝑝𝑝̂ = 𝐺𝐺̅ /2 be its sample MAF. Under Hardy-

Weinberg equilibrium, the variance of the genotype is estimated by 𝜎𝜎�𝑔𝑔2 = 2𝑝𝑝̂ (1 − 𝑝𝑝̂ ). Or
we can use a more robust variance estimator (Jakobsdottir and McPeek 2013) given by
𝜎𝜎�𝑔𝑔2 = (𝑛𝑛 − 1)−1 𝑮𝑮𝑇𝑇 𝑾𝑾𝑾𝑾,

where 𝑾𝑾 = 𝚽𝚽 −1 − 𝚽𝚽 −1 𝟏𝟏𝑛𝑛 (𝟏𝟏𝑇𝑇𝑛𝑛 𝚽𝚽 −1 𝟏𝟏𝑛𝑛 )−1 𝟏𝟏𝑇𝑇𝑛𝑛 𝚽𝚽 −1 . Finally, the L-BRAT test statistic can
be defined as

L-BRAT =

𝑈𝑈02

Var0 �𝑈𝑈0 �

𝒀𝒀, 𝑿𝑿�

=

2

�𝑨𝑨𝑇𝑇 𝑮𝑮�
𝑇𝑇
Var0 �𝑨𝑨 𝑮𝑮 �

𝒀𝒀, 𝑿𝑿�

=

�𝑨𝑨𝑇𝑇 𝑮𝑮�

2

�𝑔𝑔2 𝑨𝑨𝑇𝑇 𝚽𝚽𝚽𝚽
𝜎𝜎

.

(7)

Under regularity conditions, L-BRAT asymptotically follows a 𝜒𝜒12 distribution under the
null hypothesis.
1.3.3

Generalized linear mixed model (GLMM)

The Generalized linear Mixed Model Association Test (GMMAT) was originally
designed to use random effects in logistic mixed models to account for population
21

structure and cryptic relatedness in case-control studies[18].To extend the GMMAT
method for case-control analysis to repeated binary data, we consider the following
logistic mixed model:
logit �𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜷𝜷 + 𝐺𝐺𝑖𝑖 𝛾𝛾 + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 , 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 ,

(8)

where 𝜇𝜇𝑖𝑖𝑖𝑖 = 𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖 = 1 � 𝐺𝐺𝑖𝑖 , 𝑿𝑿𝑖𝑖𝑖𝑖 , 𝑎𝑎𝑖𝑖 , 𝑟𝑟𝑖𝑖𝑖𝑖 � is the probability of a binary response at time 𝑡𝑡𝑖𝑖𝑖𝑖
for individual 𝑖𝑖, conditional on his/her genotype, covariates, and random effects 𝑎𝑎𝑖𝑖 and

𝑟𝑟𝑖𝑖𝑖𝑖 , 𝜷𝜷 and 𝛾𝛾 are the same as defined in model (1), 𝑎𝑎𝑖𝑖 is the individual random effect, and

𝑟𝑟𝑖𝑖𝑖𝑖 is the individual-specific time-dependent random effect. The two random effects were

used to capture the correlation among repeated measures in gene-based association test

for longitudinal traits [19]. Here, 𝑎𝑎𝑖𝑖 's are assumed to be independent and 𝑎𝑎𝑖𝑖 ∼ 𝑁𝑁(0, 𝜎𝜎𝑎𝑎2 ).
The vector of time-dependent random effects 𝒓𝒓𝑖𝑖 = (𝑟𝑟𝑖𝑖1 , … , 𝑟𝑟𝑖𝑖,𝑛𝑛𝑖𝑖 ) has a multivariate

normal distribution, 𝒓𝒓𝑖𝑖 ∼ 𝑀𝑀𝑀𝑀𝑀𝑀(𝟎𝟎, 𝜎𝜎𝑟𝑟2 𝑹𝑹𝑖𝑖 ), where an AR(1) structure is assumed for the

correlation matrix 𝑹𝑹𝑖𝑖 , in which 𝜏𝜏 is the unknown parameter. The binary responses 𝑌𝑌𝑖𝑖𝑖𝑖 are
assumed to be independent given the random effects 𝑎𝑎𝑖𝑖 and 𝑟𝑟𝑖𝑖𝑖𝑖 . Note that the first

relatedness matrix of the random effects in the original GMMAT paper is genetic

relationship matrix, but in our model for the longitudinal data, the two relatedness
matrices correspond to the individual random effect and the individual specific timedependent random effect.
To construct a score test for the null hypothesis 𝐻𝐻0 : 𝛾𝛾 = 0 vs. the alternative 𝐻𝐻1 : 𝛾𝛾 ≠

0, we use the penalized quasi-likelihood method [20] to fit the null logistic mixed model
� 0 , 𝜎𝜎�𝑎𝑎2 , 𝜎𝜎�𝑟𝑟2 and 𝜏𝜏̂ 0 [18].
and obtain the null estimates of 𝜷𝜷, 𝜎𝜎𝑎𝑎2 , 𝜎𝜎𝑟𝑟2 and 𝜏𝜏, denoted by 𝜷𝜷
22

� and 𝒓𝒓�, can be
Similarly, the best linear unbiased predictor (BLUP) of random effects, 𝒂𝒂
obtained. Then, the resulting score function for 𝛾𝛾 is

(9)

� 0 ),
𝑆𝑆0 = 𝑆𝑆(𝛾𝛾)|𝜷𝜷�0 ,0,𝜎𝜎�𝑎𝑎2,𝜎𝜎�𝑟𝑟2,𝜏𝜏�0,𝒂𝒂�,𝒓𝒓� = (𝑩𝑩𝑩𝑩)𝑇𝑇 (𝒀𝒀 − 𝝁𝝁

� 0 + 𝑩𝑩𝒂𝒂
� + 𝒓𝒓�) is a vector of fitted values under 𝐻𝐻0 .
� 0 = logit −1 (𝑿𝑿𝜷𝜷
where 𝝁𝝁

In GMMAT, the null variance of the score 𝑆𝑆0 is evaluated prospectively [18], i.e.,

Var0 (𝑆𝑆0 | 𝑮𝑮, 𝑿𝑿) = (𝑩𝑩𝑩𝑩)𝑇𝑇 𝑷𝑷𝑷𝑷𝑷𝑷, where 𝑷𝑷 = 𝚿𝚿 −1 − 𝚿𝚿 −1 𝑿𝑿(𝑿𝑿𝑇𝑇 𝚿𝚿 −1 𝑿𝑿)−1 𝑿𝑿𝑇𝑇 𝚿𝚿 −1 , and 𝚿𝚿 =

� . Here 𝚪𝚪�0 and 𝑹𝑹
� are 𝚪𝚪 and 𝑹𝑹 evaluated at (𝜷𝜷, 𝛾𝛾, 𝜎𝜎𝑎𝑎2 , 𝜎𝜎𝑟𝑟2 , 𝜏𝜏) =
𝚪𝚪�0−1 + 𝜎𝜎�𝑎𝑎2 𝑩𝑩𝑩𝑩𝑇𝑇 + 𝜎𝜎�𝑟𝑟2 𝑹𝑹

� 0 , 0, 𝜎𝜎�𝑎𝑎2 , 𝜎𝜎�𝑟𝑟2 , 𝜏𝜏̂ 0 �, where 𝚪𝚪 is the same as defined in Eq. (3) and 𝑹𝑹 = diag{𝑹𝑹1 , … , 𝑹𝑹𝑛𝑛 } is
�𝜷𝜷
a block diagonal matrix. The GMMAT test statistic can be written as

1.3.4

𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 =

𝑆𝑆02

Var0 �𝑆𝑆0 �

𝑮𝑮, 𝑿𝑿�

RGMMAT retrospective test

=

𝟐𝟐

� 0 )�
�(𝑩𝑩𝑩𝑩)𝑇𝑇 (𝒀𝒀−𝝁𝝁
(𝑩𝑩𝑩𝑩)𝑇𝑇 𝑷𝑷𝑷𝑷𝑷𝑷

(10)

.

Like L-BRAT, we can construct a retrospective test to assess the significance of the
GLMM score function of Eq. (9), which we call RGMMAT, based on the quasilikelihood model of 𝑮𝑮 in Eq. (6). Thus, we define the RGMMAT statistic by
RGMMAT =

𝑆𝑆02

Var0 �𝑆𝑆0 �

𝒀𝒀, 𝑿𝑿�

=

2

�𝑪𝑪𝑇𝑇 𝑮𝑮�
𝑇𝑇
Var0 �𝑪𝑪 𝑮𝑮 �

𝒀𝒀, 𝑿𝑿�

=

�𝑪𝑪𝑇𝑇 𝑮𝑮�

2

�𝑔𝑔2 𝑪𝑪𝑇𝑇 𝚽𝚽𝑪𝑪
𝜎𝜎

,

� 0 ) is the 𝑛𝑛-dimensional vector of phenotypic residuals at the
where 𝑪𝑪 = 𝑩𝑩𝑇𝑇 (𝒀𝒀 − 𝝁𝝁

(11)

individual level by summing over all time points for an individual, and the phenotypic
residuals are obtained by fitting the null logistic mixed model. Both the GMMAT and
RGMMAT test statistics are assumed to have 𝜒𝜒12 asymptotic null distributions.
1.3.5

Simulation studies
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We performed simulation studies to evaluate the type I error and power of the two
retrospective tests we propose, and compared them to the prospective GEE and GMMAT
methods. We also assessed sensitivity of L-BRAT and RGMMAT in the presence of
model misspecification and ascertainment. In the simulations, we considered two
different trait models and three different ascertainment schemes. Because both the LBRAT and GEE methods require specification of a working correlation matrix, we
implemented three working correlation structures: (1) independent, (2) AR(1), and (3) a
mixture of exchangeable and AR(1).
To generate genotypes, we first simulated 10,000 chromosomes over a 1 Mb region
using a coalescent model that mimics the linkage disequilibrium (LD) and recombination
rates of the European population [21]. We then randomly selected 1,000 non-causal
single nucleotide polymorphisms (SNPs) with MAF > 0.05. In addition, we generated
two causal SNPs that were assumed to influence the trait value with epistasis. In the type
I error simulations, we tested association at the 1,000 non-causal SNPs. In each
simulation setting, we generated 1,000 sets of phenotypes at five time points. Putting
together, 106 replicates were used for the type I error evaluation. In the power
simulations, we tested the first of the two causal SNPs and empirical power was assessed
using 1,000 simulation replicates. In all tests considered, the genotypes at the untested
causal SNP(s) were assumed to be unobserved.
Trait models
We simulated two types of binary trait models at five time points, in which the two
unlinked causal SNPs were assumed to act on the phenotype epistatically. The first type
is a logistic mixed model, given by
24

𝑌𝑌𝑖𝑖𝑖𝑖 |𝑿𝑿𝑖𝑖𝑖𝑖 , 𝐺𝐺𝑖𝑖(1) , 𝐺𝐺𝑖𝑖(2) , 𝑎𝑎𝑖𝑖 , 𝑟𝑟𝑖𝑖𝑖𝑖 ∼ Bernoulli �𝜇𝜇𝑖𝑖𝑖𝑖 �,

logit �𝜇𝜇𝑖𝑖𝑖𝑖 � = −2.5 + 0.2(𝑗𝑗 − 1) + 0.5𝑋𝑋𝑖𝑖𝑖𝑖(1) + 0.5𝑋𝑋𝑖𝑖(2) + 𝜃𝜃1�𝐺𝐺𝑖𝑖(1) >0,𝐺𝐺𝑖𝑖(2) >0� + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 ,

where 𝑋𝑋𝑖𝑖𝑖𝑖(1) is a continuous, time-varying covariate generated independently from a

standard normal distribution, 𝑋𝑋𝑖𝑖(2) is a binary, time-invariant covariate taking values 0 or
1 with a probability of 0.5, 𝐺𝐺𝑖𝑖(1) and 𝐺𝐺𝑖𝑖(2) are the genotypes of individual 𝑖𝑖 at the two
causal SNPs, 𝜃𝜃 is a scalar parameter encoding the effect of the causal SNPs,

1�𝐺𝐺𝑖𝑖(1)>0,𝐺𝐺𝑖𝑖(2)>0� is an indicator function that takes value 1 when individual 𝑖𝑖 has at least
one copy of the minor allele at both the causal SNPs, 𝑎𝑎𝑖𝑖 and 𝑟𝑟𝑖𝑖𝑖𝑖 are the individual-level

time-independent and time-dependent random effects, respectively. Here we assume 𝑎𝑎𝑖𝑖 ∼

𝑁𝑁(0, 𝜎𝜎𝑎𝑎2 ) and 𝒓𝒓𝑖𝑖 = (𝑟𝑟𝑖𝑖1 , … , 𝑟𝑟𝑖𝑖5 ) ∼ 𝑀𝑀𝑀𝑀𝑀𝑀(𝟎𝟎, 𝜎𝜎𝑟𝑟2 𝑹𝑹), where 𝑹𝑹 is a 5 × 5 correlation matrix

specified by the AR(1) structure with a correlation coefficient 𝜏𝜏. The two causal SNPs are
assumed to be unlinked with MAFs 0.1 and 0.5, respectively. The variance components
are set to 𝜎𝜎𝑎𝑎2 = 𝜎𝜎𝑟𝑟2 = 0.64 and 𝜏𝜏 = 0.7.

The second type of trait model we considered is a liability threshold model in which

an underlying continuous liability determines the outcome value based on a threshold.
Specifically, the phenotype 𝑌𝑌𝑖𝑖𝑖𝑖 is given by

𝑌𝑌𝑖𝑖𝑖𝑖 = 1 if 𝐿𝐿𝑖𝑖𝑖𝑖 > 0,

with 𝐿𝐿𝑖𝑖𝑖𝑖 = −2.0 + 0.2(𝑗𝑗 − 1) + 0.5𝑋𝑋𝑖𝑖𝑖𝑖(1) + 0.5𝑋𝑋𝑖𝑖(2) + 𝜃𝜃1�𝐺𝐺𝑖𝑖(1) >0,𝐺𝐺𝑖𝑖(2)>0� + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖
+ 𝑒𝑒𝑖𝑖𝑖𝑖 ,
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where 𝐿𝐿𝑖𝑖𝑖𝑖 is the underlying liability for individual 𝑖𝑖 at time 𝑡𝑡𝑖𝑖𝑖𝑖 , and 𝑒𝑒𝑖𝑖𝑖𝑖 ∼ 𝑁𝑁(0, 𝜎𝜎𝑒𝑒2 )

represents independent noise, with 𝜎𝜎𝑒𝑒2 = 0.64. All other parameters are the same as those
in the logistic mixed model.

In both models, we included a time effect and assumed that the mean of the outcome
increases with time. The effect of the causal SNPs was set to 𝜃𝜃 = 0.34 in the type I error
simulations. For the power evaluation, we considered a range of values for 𝜃𝜃, where we

set 𝜃𝜃 = 0.3, 0.32, 0.34, 0.36, and 0.38. At the given parameter values, the prevalence of
the event of interest ranges from 12.8% to 27.7% over time. The proportion of the

phenotypic variance explained by the two causal SNPs ranges from 0.69% to 1.10% in
the logistic mixed model, and from 0.49% to 0.78% in the liability threshold model.
Sampling designs
We considered three different sampling designs. In the “random” sampling scheme,
the sample contains 2,000 individuals that were randomly selected from the population
regardless of their phenotypes. Thus, ascertainment is population based. In the “baseline”
sampling scheme, we sampled 1,000 case subjects and 1,000 control subjects according
to their outcome value at baseline only. In the “sum” sampling scheme, individuals were
stratified into three strata (1, 2, and 3) based on a total count that sums each subject’s
response over time, where samples in stratum 1 never experienced the event of interest,
i.e., ∑𝑗𝑗 𝑌𝑌𝑖𝑖𝑖𝑖 = 0, samples in stratum 2 sometimes experienced the event, i.e., 0 < ∑𝑗𝑗 𝑌𝑌𝑖𝑖𝑖𝑖 <
𝑛𝑛𝑖𝑖 , and samples in stratum 3 always experienced the event, i.e., ∑𝑗𝑗 𝑌𝑌𝑖𝑖𝑖𝑖 = 𝑛𝑛𝑖𝑖 . Following

the outcome-dependent sampling design for longitudinal binary data [17], we selected
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100, 1,800, and 100 individuals from the three strata respectively to oversample subjects
who have response variation over the course of the study.
1.3.6

Application to cocaine use data from VACS

We illustrated the utility of our proposed methods by analyzing a GWAS dataset of
cocaine use from VACS [22]. VACS is a multi-center, longitudinal observational study
of HIV infected and uninfected veterans whose primary objective is to understand the
risk of alcohol and other substance abuse in individuals with HIV infection. We analyzed
longitudinal cocaine use in patient surveys collected at six clinic visits on 2,470
participants. Among them, 69.8% are African Americans (AAs), 19.3% are European
Americans (EAs), and 10.9% are of other races. We considered the responses at each
visit as 0 if individuals had never tried cocaine or had not used cocaine in the last year,
and as 1 if individuals had used cocaine in the last year. The proportion of case subjects
at each visit ranges from 13.7% (𝑛𝑛 = 192) to 24.3% (𝑛𝑛 = 526), and the missing rate at
each visit ranges from 3.0% to 44.2%.

All samples were genotyped on the Illumina OmniExpress BeadChip. After data
cleaning, there are 2,458 individuals available for genotype imputation. IMPUTE2 [23]
was used for imputation using the 1000 Genomes Phase 3 data as a reference panel. We
excluded subjects who did not meet either of the following criteria: (1) completeness (i.e.,
proportion of successfully imputed SNPs) > 95% and (2) empirical self-kinship < 0.525
(i.e., empirical inbreeding coefficient < 0.05). Based on the above criteria, 2,231
individuals were retained in the analysis, with 2,114 males and 117 females, of whom
1,557 are AAs, 431 are EAs, and 243 are of other races. There are 1,433 individuals who
had never used cocaine during the study period, 639 individuals who sometimes used
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cocaine, i.e., exhibited response variation, and 159 individuals who had used cocaine at
least once every year over the course of the study. SNPs that satisfied all of the following
quality-control conditions were included in the analysis: (1) call rate > 95%, (2) HardyWeinberg 𝜒𝜒 2 statistic P-value > 10-6, and (3) MAF > 1%. All together there are a final set
of 10,215,072 SNPs retained in the analysis. The VACS dataset, both the genotype file in
the plink format and the phenotype files including the longitudinally measured cocaine
use and the covariates, will be deposited to dbGap (https://www.ncbi.nlm.nih.gov/gap).
Pathway and enrichment analyses
We then performed pathway analysis on the top SNPs for which at least one of the
longitudinal tests had a P-value < 5 × 10−5 using the Ingenuity Pathway Analysis (IPA).
The Ingenuity database gathers information from manually reviewed literature, as well as
large public databases. In this analysis, the top SNPs’ RSID were uploaded into the IPA
and mapped, if possible, to the reference set in the Ingenuity knowledge. The IPA
performs a Fisher’s Exact test to determine whether the submitted SNP list belongs to
genes of a particular function annotation more than expected by chance. We report below
both Fisher’s exact test P-value and adjusted P-value using Benjamini-Hochberg method
for multiple testing adjusting for the number of ontologies tested. We consider pathways
with adjusted P-value less than 0.05 to be significant. We also performed an enrichment
analysis to see whether the top SNPs in our analysis are more likely to regulate brain
gene expression.
Replication data
We used an independent cocaine dependence case-control GWAS from the YalePenn study [24] to replicate the top findings from our longitudinal analysis results in
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VACS. The summary statistics from the Yale-Penn cocaine dependence GWAS were
obtained. Note that the lifetime cocaine dependence diagnosis was made using the SemiStructured Assessment for Drug Dependence and Alcoholism (SSADDA) [25], which is
different from the outcome used in VACS, and there were no longitudinal phenotype
measures in Yale-Penn. Pathway analysis using IPA was applied to the summary
statistics of Yale-Penn on the top SNP list identified from VACS. The Fisher’s exact test
P-values were calculated for each pathway to evaluate if there were more associated
SNPs than would be expected by chance.

1.4 Results
1.4.1

Type I error assessment

To assess type I error, we tested for association at unlinked and unassociated SNPs.
Table 1.1 gives the empirical type I error of the L-BRAT, RGMMAT, GEE, and
GMMAT tests, based on 106 replicates, at the nominal type I error level 𝛼𝛼, for 𝛼𝛼 = 0.05,

0.01, 0.001, and 0.0001. In all simulations, the type I error of the two retrospective tests,
L-BRAT and RGMMAT, exhibited no inflation at any of the nominal levels considered.
In contrast, the prospective GEE tests, regardless of the choice of working correlation,
had inflated type I error at most of the nominal levels in all settings. This is likely due to
the fact that the asymptotic distribution of robust sandwich variance estimators used in
GEE are not well calibrated. The inflated type I error was also reported in longitudinal
GWAS with quantitative traits using GEE [3]. In GMMAT, the type I error was much
lower than the nominal level when 𝛼𝛼 = 0.05, 0.01, 0.001, and 0.0001. These results

demonstrate that the two retrospective tests, L-BRAT and RGMMAT, are robust to trait
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model misspecification and ascertainment, whereas GEE has type I error inflation and
GMMAT is overly conservative. Overall, the choice of the working correlation matrix
does not have much impact on the type I error of the L-BRAT method.
Table 1.1. Empirical type I error of L-BRAT, RGMMAT, GEE, and GMMAT, based on 106
replicates.
Test

Level

Logistic Mixed Model

Liability Threshold Model

Random

Baseline

Sum

Random

Baseline

Sum

0.05

5.38 × 10-2

5.08 × 10-2

5.27 × 10-2

5.36 × 10-2

5.19 × 10-2

5.38 × 10-2

GEE

0.01

1.18 × 10-2

1.04 × 10-2

1.13 × 10-2

1.17 × 10-2

1.07 × 10-2

1.17 × 10-2

(ind)

0.001

1.32 × 10-3

1.16 × 10-3

1.23 × 10-3

1.37 × 10-3

1.14 × 10-3

1.37 × 10-3

0.0001

1.67 × 10-4

1.28 × 10-4

1.43 × 10-4

1.34 × 10-4

1.36 × 10-4

1.76 × 10-4

0.05

5.36 × 10-2

5.02 × 10-2

5.26 × 10-2

5.34 × 10-2

5.17 × 10-2

5.37 × 10-2

GEE

0.01

1.16 × 10-2

1.04 × 10-2

1.12 × 10-2

1.16 × 10-2

1.06 × 10-2

1.17 × 10-2

(AR1)

0.001

1.31 × 10-3

1.13 × 10-3

1.21 × 10-3

1.36 × 10-3

1.14 × 10-3

1.36 × 10-3

0.0001

1.73 × 10-4

1.19 × 10-4

1.37 × 10-4

1.32 × 10-4

1.35 × 10-4

1.78 × 10-4

0.05

5.34 × 10-2

5.07 × 10-2

5.26 × 10-2

5.34 × 10-2

5.19 × 10-2

5.37 × 10-2

0.01

1.17 × 10-2

1.04 × 10-2

1.13 × 10-2

1.16 × 10-2

1.07 × 10-2

1.17 × 10-2

0.001

1.29 × 10-3

1.17 × 10-3

1.22 × 10-3

1.38 × 10-3

1.14 × 10-3

1.36 × 10-3

0.0001

1.70 × 10-4

1.29 × 10-4

1.37 × 10-4

1.31 × 10-4

1.30 × 10-4

1.70 × 10-4

0.05

3.89 × 10-2

3.53 × 10-2

4.76 × 10-2

4.80 × 10-2

4.89 × 10-2

4.91 × 10-2

0.01

6.07 × 10-3

5.24 × 10-3

9.08 × 10-3

9.29 × 10-3

9.51 × 10-3

9.33 × 10-3

0.001

4.29 × 10-4

3.74 × 10-4

7.84 × 10-4

8.63 × 10-4

8.96 × 10-4

8.33 × 10-4

0.0001

2.20 × 10-5

2.20 × 10-5

6.80 × 10-5

6.30 × 10-5

9.10 × 10-5

8.80 × 10-5

0.05

4.93 × 10-2

4.91 × 10-2

4.98 × 10-2

5.01 × 10-2

4.99 × 10-2

4.98 × 10-2

L-BRAT

0.01

9.45 × 10-3

9.60 × 10-3

9.84 × 10-3

9.90 × 10-3

9.75 × 10-3

9.55 × 10-3

(ind)

0.001

8.30 × 10-4

9.78 × 10-4

9.24 × 10-4

9.55 × 10-4

9.45 × 10-4

8.78 × 10-4

0.0001

7.20 × 10-5

9.50 × 10-5

8.20 × 10-5

8.20 × 10-5

9.40 × 10-5

9.20 × 10-5

0.05

4.93 × 10-2

4.88 × 10-2

4.97 × 10-2

4.99 × 10-2

4.98 × 10-2

4.97 × 10-2

GEE(mix)

GMMAT

L-BRAT
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(AR1)

0.01

9.48 × 10-3

9.72 × 10-3

9.78 × 10-3

9.84 × 10-3

9.76 × 10-3

9.55 × 10-3

0.001

8.26 × 10-4

9.62 × 10-4

9.22 × 10-4

9.17 × 10-4

9.47 × 10-4

8.48 × 10-4

0.0001

8.80 × 10-5

9.60 × 10-5

8.20 × 10-5

7.10 × 10-5

1.02 × 10-4

8.90 × 10-5

0.05

4.93 × 10-2

4.91 × 10-2

4.99 × 10-2

5.01 × 10-2

4.98 × 10-2

4.98 × 10-2

L-BRAT

0.01

9.57 × 10-3

9.61 × 10-3

9.86 × 10-3

9.88 × 10-3

9.79 × 10-3

9.54 × 10-3

(mix)

0.001

8.35 × 10-4

9.86 × 10-4

9.26 × 10-4

9.57 × 10-4

9.37 × 10-4

8.78 × 10-4

0.0001

8.20 × 10-5

1.01 × 10-4

8.60 × 10-5

7.40 × 10-5

9.70 × 10-5

8.90 × 10-5

0.05

4.72 × 10-2

4.91 × 10-2

4.98 × 10-2

4.93 × 10-2

4.99 × 10-2

4.98 × 10-2

0.01

8.76 × 10-3

9.64 × 10-3

9.85 × 10-3

9.63 × 10-3

9.78 × 10-3

9.55 × 10-3

0.001

7.20 × 10-4

9.52 × 10-4

9.09 × 10-4

9.12 × 10-4

9.43 × 10-4

8.75 × 10-4

0.0001

6.80 × 10-5

8.90 × 10-5

8.20 × 10-5

7.70 × 10-5

9.10 × 10-5

9.30 × 10-5

RGMMAT

1.4.2

Power comparison

To compare power, we considered five effect sizes at the two causal SNPs, and tested
association between the trait and the first causal SNP. Empirical power was calculated at
the significance level 10-3, based on 1,000 simulated replicates. Figure 1 demonstrates the
power results for each method. In all the simulation settings, the retrospective tests
consistently had higher power than the prospective tests. The L-BRAT association tests
under three different working correlation structures had similar power. The RGMMAT
method also achieved high power. In contrast, the prospective GEE methods had the
lowest power in all settings except under the baseline sampling and the liability threshold
model, in which GMMAT performed the worst in power. Overall, we found that the
baseline sampling scheme generated the highest power under different trait models, while
the sum sampling scheme had a power gain over the random sampling scheme under the
logistic mixed model, but was less powerful under the liability threshold model. These
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results suggest that L-BRAT and RGMMAT outperform the prospective tests, and the
power of L-BRAT is not sensitive to the choice of the working correlation structure.

Figure 1.1. Empirical power of L-BRAT, RGMMAT, GEE, and GMMAT. Power is based
on 1,000 simulated replicates at five time points with 𝛼𝛼 = 10−3. In the upper panel, the trait is
simulated by the logistic mixed model, and in the lower panel, it is by the liability threshold
model. Power results are demonstrated in samples of 2,000 individuals according to three
different ascertainment schemes: random, baseline, and sum. This figure appears in color in the
electronic version of this article.

1.4.3

Analysis of Longitudinal Cocaine Use Data from VACS

Genome-wide association testing for longitudinal cocaine use was performed using LBRAT, RGMMAT, and the prospective GEE and GMMAT tests in the entire VACS
sample. Sex, age at baseline, HIV status, and time were included as covariates in the
analysis. The top ten principal components (PCs) that explained 89.4% of the total
genetic variation were included as covariates to control for population structure. We
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considered two working correlation structures: independent and AR(1). For the L-BRAT
and RGMMAT methods, the GRM was calculated using the LD pruned SNPs with
MAF > 0.05.
To compare the performance of longitudinal association analysis with that of
univariate analysis on the summary metrics of cocaine use in VACS, we considered two
alternative cocaine phenotypes: baseline and trajectories. Longitudinal cocaine use
trajectories were obtained using a growth mixture model that clusters longitudinal data
into discrete growth trajectory curves [26]. We fit a logistic model with a polynomial
function of time. The number of groups was chosen based on the Bayesian information
criterion (BIC). Each individual was then assigned to the trajectory with the highest
probability of membership. Figure 2 shows the four cocaine use trajectory groups
identified in the VACS sample. They were labeled as mostly never (0, 𝑛𝑛 = 1,682),

moderate decrease (1, 𝑛𝑛 = 296), elevated chronic (2, 𝑛𝑛 = 86), and mostly frequent (3,
𝑛𝑛 = 167). We used CARAT, a case-control retrospective association test [10], for the
analysis of cocaine use at baseline, adjusted for sex, age at baseline, and HIV status.

Cumulative logit model was used to test for association between the four ordered cocaine
use trajectory groups and each of the SNPs, with adjustment for sex, age at baseline, HIV
status, and the top ten PCs.
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Figure 1.2. Group-based cocaine use trajectories in VACS. Dashed lines represent the
estimated trajectories, solid lines represent the observed mean cocaine use for each trajectory
group. Time is the number of years since the baseline visit.

None of the retrospective tests exhibited evidence of inflation in the quantile-quantile
(Q-Q) plot. The genomic control inflation factors were 0.993 and 0.991 for the L-BRAT
genome scan under the independent and AR(1) working correlation, respectively, and
0.984 for the RGMMAT analysis. The prospective GEE tests showed some evidence of
deflation in the Q-Q plot. The genomic control factors were 0.938 and 0.937 for the GEE
tests under the independent and AR(1) working correlation. The most conservative test
was GMMAT, with a genomic control factor 0.802.
Table 1.2 reports the results for SNPs for which at least one of the longitudinal tests
gives a P-value < 2 × 10−7 . Among them, the L-BRAT tests produced the smallest P-

values, RGMMAT and the trajectory-based analysis had comparable results, while GEE,
GMMAT, and CARAT generated much larger P-values. Among the top SNPs listed in
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Table 1.2, there are two SNPs, rs551879660 and rs150191017, located at 3p12 and 13q12
respectively, that reach the genome-wide significance (P = 2.00 × 10−8 and

3.77 × 10−8 , respectively). Each of these SNPs was reported to have MAF < 1% in the
1000 Genomes (MAF = 0.68% and 0.98%, respectively). The MAFs of the two SNPs

were 1.2% and 1.1% in the entire VACS sample, respectively, and were slightly higher in
the AA sample (MAF = 1.6% and 1.5%, respectively). Although both SNPs have MAF >
1%, given the small sample size of VACS, there is limited information on them. SNP
rs150191017 is located 31.5 kb from the gene AL161616.2 which was reported to be
associated with venlafaxine treatment response in a generalized anxiety disorder GWAS
[27]. A cluster of five SNPs in LD, rs76386683, rs114386843, rs186274502,
rs376616438, and rs187855416, located at 9q33, showed association with longitudinal
cocaine use (P = 1.85 × 10−7 − 1.93 × 10−7 ). They are near OR1L4, an olfactory

receptor gene that was reported to be associated with major depressive disorder [28]. A
cluster of olfactory receptor genes between OR3A1 and OR3A2 that belong to the
olfactory receptor gene family were identified in a recent GWAS of cocaine dependence
and related traits [24]. The other three SNPs, rs188222191, rs1014278, rs75132056, are
located at 5q21 (P = 1.28 × 10−7 , 1.43 × 10−7 and 8.92 × 10−8 , respectively), close to
the gene EFNA5, which was identified in several GWAS to be associated with bipolar
disorder and schizophrenia [29]. There was also evidence of association with
rs114629793 (P = 8.65 × 10−8 ). This SNP is in an intron of the gene encoding PSD3,

located at 8p22. Recently, two schizophrenia GWAS have identified association between
PSD3 and schizophrenia [30,31], and one study has shown that PSD3 is associated with
paliperidone treatment response in schizophrenic patients [32]. Gene network analysis
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revealed that PSD3 is one of the differentially expressed hub genes that involve
dysfunction of brain reward circuitry in cocaine use disorder [33].
Table 1.2. SNPs with P-value < 2×10−7 in at least one of the longitudinal tests in the entire VACS
sample. The smallest P-value among all tests at the given SNPs are in bold. a CARAT applied to cocaine
use at baseline, b Cumulative logit model applied to the four ordered cocaine use trajectory group.
Chr.

Gene Region SNP

Position

MAF

GEE
(ind)

GEE
(AR1)

GMMAT

L-BRAT L-BRAT RGMMA CARATa CLb
(ind)
(AR1)
T
(traj)
(BL)

-4

-4

-4

-8

-6

-5

-4

-5

-6

-5

-5

-7

-7

-6

-5

-5

-5

-5

-4

-7

-7

-6

-5

-5

-5

-5

-4

-8

-7

-6

-4

-5

-4

-8

-7

-6

-4

-6

-7

-6

-4

-6

3

NIPA2P2

rs551879660 75,146,492

0.012

1.87 × 10 7.14 × 10 9.07 × 10 2.00 × 10 3.19 × 10 4.13 × 10 5.78 × 10 3.35 × 10

5

EFNA5

rs188222191 105,411,547 0.042

6.86 × 10 1.65 × 10 8.87 × 10 1.28 × 10 4.17 × 10 2.69 × 10 8.95 × 10 2.72 × 10

rs1014278

1.02 × 10 1.10 × 10 1.24 × 10 1.50 × 10 1.43 × 10 4.88 × 10 5.94 × 10 3.00 × 10

105,471,506 0.057

rs75132056 105,480,442 0.05

1.05 × 10 2.42 × 10 1.89 × 10 8.92 × 10 2.89 × 10 8.55 × 10 2.59 × 10 2.31 × 10
3.12 × 10 4.73 ×10

0.012

-4

-4

8

PSD3

rs114629793 18,403,754

9

OR1L4

rs76386683 125,467,023 0.012

1.48 × 10 9.15 × 10 2.86 × 10 1.03 ×10 1.93 × 10 5.92 × 10 4.80 × 10 3.30 × 10

rs114386843 125,469,425 0.012

1.47 × 10 9.05 × 10 2.82 × 10 1.01 × 10 1.88 × 10 5.78 × 10 4.75 × 10 3.22 × 10

rs186274502 125,471,416 0.012

1.47 × 10 9.05 × 10 2.82 × 10 1.01 × 10 1.88 × 10 5.78 × 10 4.75 × 10 3.22 × 10

rs376616438 125,472,267 0.012

1.44 × 10 8.95 × 10 2.77 × 10 9.79 × 10 1.85 × 10 5.62 × 10 4.79 × 10 3.20 × 10

rs187855416 125,474,459 0.012

1.44 × 10 8.95 × 10 2.77 × 10 9.79 × 10 1.85 × 10 5.62 × 10 4.79 × 10 3.20 × 10

1.44 × 10 8.65 × 10 3.60 × 10 2.82 × 10 5.12 × 10 3.06 × 10

-4

-5

-4

-6

-4

-5

-4

-6

-7

-6

-4

-6

-4

-5

-4

-6

-7

-6

-4

-6

-4

-5

-4

-7

-7

-6

-4

-6

-4

-5

-4

-7

-7

-6

-4

-6

-5

-5

-4

-7

-7

-5

-4

-6

-5

-5

-5

-8

-7

-7

-4

-7

11

AP000851.1

rs1397806
102,509,700 0.03
93

2.60 × 10 1.04 × 10 2.78 × 10 5.83 × 10 1.26 × 10 1.35 × 10 1.06 × 10 2.00 × 10

13

AL161616.2

rs1501910
31,962,649
17

4.26 × 10 9.72 × 10 7.32 × 10 3.77 × 10 3.09 × 10 7.87 × 10 3.74 × 10 5.48 × 10

0.011

We further analyzed the data separately in each population, adjusted for the top ten
PCs obtained within the group, and then combined the results from the three groups by
meta-analysis using the optimal weights for score statistics that have essentially the same
power as the inverse variance weighting [34]. The results from the three groups (AAs,
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EAs and other races) were combined by meta-analysis. The meta-analysis P-values were
of the same order of magnitude as that obtained from the entire sample adjusted for
population structure for each longitudinal test (Table 1.3). All the top twelve SNPs listed
in Table 1.3 had a meta-analysis P-value < 8 × 10−7 in at least one of the longitudinal

tests. Among them, the L-BRAT test with either an independent or AR(1) working
correlation gave the smallest meta-analysis P-values.

Table 1.3. Meta-analysis results of the top twelve SNPs from Table 1.2 in the VACS data. The smallest
P-value among all tests at the given SNPs are in bold.

Chr Gene Region SNP

Position

GEE
(ind)

GEE
(AR1)

GMMAT

L-BRAT
(ind)

L-BRAT
(AR1)

RGMMAT

3

NIPA2P2

rs551879660

75,146,492

1.81 × 10-4

5.86 × 10-4

8.98 × 10-4

5.26 × 10-8

6.41 × 10-6

6.49 × 10-5

5

EFNA5

rs188222191

105,411,547

7.57 × 10-6

1.28 × 10-5

1.80 × 10-4

2.55 × 10-7

5.52 × 10-7

1.10 × 10-5

rs1014278

105,471,506

1.26 × 10-5

8.44 × 10-6

3.15 × 10-4

1.03 × 10-6

5.59 × 10-7

2.44 × 10-5

rs75132056

105,480,442

1.31 × 10-5

2.00 × 10-5

4.24 × 10-4

7.31 × 10-7

1.27 × 10-6

3.56 × 10-5

8

PSD3

rs114629793

18,403,754

2.92 × 10-4

4.31 × 10-4

1.66 × 10-4

1.79 × 10-7

7.98 × 10-7

6.83 × 10-6

9

OR1L4

rs76386683

125,467,023

1.44 × 10-4

8.78 × 10-5

3.75 × 10-4

2.32 × 10-6

5.12 × 10-7

1.46 × 10-5

rs114386843

125,469,425

1.42 × 10-4

8.62 × 10-5

3.68 × 10-4

2.25 × 10-6

4.97 × 10-7

1.41 × 10-5

rs186274502

125,471,416

1.42 × 10-4

8.62 × 10-5

3.68 × 10-4

2.25 × 10-6

4.97 × 10-7

1.41 × 10-5

rs376616438

125,472,267

1.39 × 10-4

8.51 × 10-5

3.60 × 10-4

2.18 × 10-6

4.86 × 10-7

1.37 × 10-5

rs187855416

125,474,459

1.39 × 10-4

8.51 × 10-5

3.60 × 10-4

2.18 × 10-6

4.86 × 10-7

1.37 × 10-5

11 AP000851.1 rs139780693

102,509,700

1.15 × 10-5

4.16 × 10-6

1.07 × 10-4

4.04 × 10-7

6.05 × 10-8

4.41 × 10-6

13 AL161616.2 rs150191017

31,962,649

3.55 × 10-5

6.77 × 10-5

1.26 × 10-4

6.68 × 10-8

5.80 × 10-7

3.12 × 10-6

The smallest P-value among all tests at the given SNPs are in bold.
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Pathway and enrichment analysis results
We identified two significant canonical pathways that belong to the neurotransmitters
and nervous system signaling. The first one is the opioid signaling pathway (P =

1.41 × 10−4 , adjusted P = 0.010), which plays an important role in opioid tolerance and
dependence. Studies have shown that chronic administration of cocaine and opioids are
associated with changes in dopamine transporters and opioid receptors in various brain
regions [35,36] . The second significant pathway is the axonal guidance signaling
pathway (P = 2.54 × 10−4 , adjusted P = 0.012), which is critical for neural development.
The mRNA expression levels of axon guidance molecules have been found to be altered
in some brain regions of cocaine-treated rats, which may contribute to drug abuseassociated cognitive impairment [37,38]. Each of the two pathways remained significant
when we performed pathway analysis, using the same P-value cutoff value to select top
SNPs, based on the L-BRAT results generated under the independence and AR(1)
working correlation, respectively. In contrast, only the opioid signaling pathway was
significant based on the results from the GEE analysis using the independent working
correlation, and only the axonal guidance signaling pathway was significant based on the
RGMMAT results, whereas neither of them remained significant based on the GMMAT
results and that from the GEE analysis with an AR(1) working correlation. These results
demonstrate that L-BRAT provides more informative association results to help identify
biological relevant pathways.
Lastly, we performed an enrichment analysis to see whether the top SNPs in our
analysis are more likely to regulate brain gene expression. We considered the local
expression quantitative trait loci (cis-eQTLs) reported in 13 human brain regions from the
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Genotype-Tissue Expression (GTEx) project [39,40], including amygdala, anterior
cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex,
hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord, and substantia
nigra. Fisher’s exact test was used to assess the enrichment of eQTLs (FDR < 0.05) in
the top 2,778 SNPs for which at least one of the longitudinal tests had a P-value < 10−4

in the VACS sample. Among the 13 brain regions, amygdala is the only region in which
eQTLs showed significant enrichment in our top SNP list (odds ratio = 2.06, P =
3.0 × 10−5 ).

Replication of top findings
Nevertheless, we performed pathway analysis using the SNP summary statistics of
Yale-Penn to replicate the two pathways identified in the VACS sample. Among the top
2,778 SNPs for which at least one of the longitudinal tests had a P-value < 10−4 , we

were able to retrieve 2,602 SNP summary statistics from Yale-Penn. Pathway analysis
was conducted on the top 84 SNPs that had a P-value < 0.05. Although none of the top
twelve SNPs in Table 1.2 had a P-value < 0.05 in the Yale-Penn AA sample, each of the
two pathways remained significant: the opioid signaling pathways (P = 5.67 × 10−4 ,
adjusted P = 3.77 × 10−3 ) and the axonal guidance signaling (P = 2.89 × 10−4 ,

adjusted P = 2.97 × 10−3 ).
1.4.4

Computation Time

The computational burden of the two retrospective tests, L-BRAT and RGMMAT,
mainly comes from the eigendecomposition of the GRM in calculating the retrospective
variance of the score functions. However, its impact on run time is minimal because the
decomposition needs to be done only once per genome scan. When fitting the null
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models, the GLMM-based methods require extra time to obtain the estimates of random
effects compared to the GEE-based methods. Once the null model is obtained, the
1/2 � −1 � −1/2
(𝒀𝒀 − 𝝁𝝁
� 0 ), in L-BRAT and the
transformed phenotypic residual vector, 𝚪𝚪�0 𝚺𝚺
0 𝚪𝚪0

� 0 , in RGMMAT, need to be calculated just once per
phenotypic residual vector, 𝒀𝒀 − 𝝁𝝁
genome scan. Thus, the computational cost of the variance in the retrospective tests is
much less than that in the prospective tests. We reported some example run times for
analysis of simulated and real data. For a simulated dataset of phenotypes at five time
points on 2,000 individuals, the GEE-based methods took 0.9 s while the GLMM-based
methods took 37 s to fit the null model. Overall, L-BRAT took 2.4 s and GEE took 27.7 s
to analyze 1,000 SNPs using a single processor on an Intel Xeon 2.6 GHz CPU machine.
In the analysis of the VACS cocaine use data, L-BRAT and GEE took 1 s while
RGMMAT and GMMAT took 2.5 min to fit the null model. Overall, L-BRAT,
RGMMAT, GEE, and GMMAT took 0.8 hr, 0.7 hr, 24.8 hr, and 26.2 hr, respectively, to
analyze a total of 10,215,072 genome-wide SNPs on Intel Xeon 2.6 GHz CPU computing
clusters with 22 nodes. These results demonstrate that L-BRAT and RGMMAT are
computationally feasible for large-scale whole-genome association studies.

1.5 Discussion
Longitudinal data can be used in GWAS to improve power for identification of
genetic variants and environmental factors that influence complex traits over time. In this
study, we have developed L-BRAT, a retrospective association testing method for
longitudinal binary outcomes. L-BRAT is based on GEE, thus it requires assumptions on
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the mean but not the full distribution of the outcome. Correct specification of the
covariance of repeated measurements within each individual is not required, instead, a
working covariance matrix is assumed. The significance of the L-BRAT association test
is assessed retrospectively by considering the conditional distribution of the genotype at
the variant of interest, given phenotype and covariate information, under the null
hypothesis of no association. Features of L-BRAT include the following: (1) it is
computationally feasible for genetic studies with millions of variants, (2) it allows both
static and time-varying covariates to be included in the analysis, (3) it allows different
individuals to have measurements at different time points, and (4) it has correct type I
error in the presence of ascertainment and trait model misspecification. For comparison,
we also propose a retrospective, logistic mixed model-based association test, RGMMAT,
which requires specification of the full distribution of the outcome. Random effects are
used to model dependence among observations for an individual. Like L-BRAT,
RGMMAT is a retrospective analysis in which genotypes are treated as random
conditional on the phenotype and covariates. As a result, RGMMAT is also more robust
to misspecification of the model for the phenotype distribution than GMMAT test.
Through simulation, we demonstrated that the type I error of L-BRAT was well
calibrated under different trait models and ascertainment schemes, whereas the type I
error of the prospective GEE method was inflated relative to nominal levels. In the
GLMM-based methods, GMMAT, a prospective analysis, was overly conservative,
whereas the retrospective version, RGMMAT, was able to maintain correct type I error.
We further demonstrated that the two retrospective tests, L-BRAT and RGMMAT,
provided higher power to detect association than the prospective GEE and GMMAT tests
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under all the trait models and ascertainment schemes considered in the simulations. The
choice of the working correlation matrix in L-BRAT resulted in little loss of power. We
applied L-BRAT and RGMMAT to longitudinal association analysis of cocaine use in the
VACS data, where we identified six novel genes that are associated with cocaine use.
Moreover, our pathway analysis identified two significant pathways associated with
longitudinal cocaine use: the opioid signaling pathway and the axonal guidance signaling
pathway. We were able to replicate both pathways in a cocaine dependence case-control
GWAS from the Yale-Penn study. Lastly, we illustrated that the top SNPs identified by
our methods are more likely to be the amygdala eQTLs in the GTEx data. The amygdala
plays an important role in the processing of memory, decision-making, and emotional
responses, and contributes to drug craving that leads to addiction and relapse [41,42].
These findings verify that L-BRAT is able to detect important loci in a genome scan and
to provide novel insights into the disease mechanism in relevant tissues. Both simulation
studies and the real data analysis suggest that, in general, L-BRAT is a more robust and at
the same time, computationally more efficient test than RGMMAT.
Although both L-BRAT and RGMMAT are proposed for population samples, they
can be easily extended to related samples in family data for whom the pedigree structure
is known. Use the similar strategy of CERAMIC, which extends the CARAT to related
samples, it would allow us to incorporate the partially missing data to enhance power. To
extend L-BRAT to family design, we could include the kinship matrix into the correlation
structure and also modify the genotypic model to incorporate the possibility that genotype
being related to covariates. Also, we should consider a more robust variance estimator
that incorporating kinship matrix into estimation.
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The L-BRAT and RGMMAT methods are designed for single-variant association
analysis of longitudinally measured binary outcomes. However, single-variant association
tests in general have limited power to detect association for low-frequency or rare
variants in sequencing studies. We have previously developed longitudinal burden test
and sequence kernel association test, LBT and LSKAT, to analyze rare variants with
longitudinal quantitative phenotypes [19]. Both tests are based on a prospective approach.
To extend L-BRAT and RGMMAT to rare variant analysis with longitudinal binary data,
we could consider either a linear statistic or a quadratic statistic that combines the
retrospective score test at each variant in a gene region. In addition, the genetic effect in
L-BRAT and RGMMAT is assumed to be constant. We could consider an extension to
allow for time-varying genetic effect so that the fluctuation of genetic contributions to the
trait value over time is well calibrated.
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Chapter 2

Variant-set Retrospective Association Tests
for Longitudinal Traits
2.1 Abstract
Longitudinal repeated measures have been increasingly used in genome-wide
association studies. The repeated measures provide an opportunity to study the temporal
development of traits and also increase the statistical power in association tests. Most of
the existing variants-set association tests are based on a population model in which
ascertainment sampling is ignored. Prospective inference with longitudinal traits and rare
variants can have inﬂated type I error when the trait model is misspecified. Here, we
propose LSRAT (Longitudinal variant-Set Retrospective Association Tests) and
RSMMAT (Retrospective variant-Set Mixed Model Association Tests), two groups of
retrospective variant-set tests that are constructed based on the genotype model given the
phenotype and covariates. RSMMAT can be viewed as a retrospective version of the
recently proposed variant-set mixed model association tests (SMMAT) and the LSRAT
tests are derived under the generalized estimation equation framework. These two
retrospective tests are robust against trait model misspecification and are computationally
more efficient than existing prospective approaches. Simulation studies showed that our
proposed tests are robust to the trait model misspecification and gain power compared to
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SMMAT. We illustrated our method in the Veterans Aging Cohort Study to evaluate the
association of repeated measures of alcohol use disorder with rare variants.

2.2 Introduction
Longitudinally measured phenotypes where each individual has multiple follow-ups
over the time are more available in genome-wide association studies (GWAS). With the
emergence of electronic health record (EHR) in large long-term studies such as UK
Biobank and Million Veteran Program, longitudinal measures are vastly being introduced
to genomic studies and GWAS. Compared to analysis based on single-time-point
measures or traits values averaged over time, longitudinal measures make full use of
phenotype information which renders more powerful genetic association tests. Moreover,
analyzing longitudinal measures enables the incorporation and adjusting for time-varying
covariates into the model. It also delivers the opportunity to study temporal development
of complex traits. Because of these merits, an increasing number of studies have
developed association tests using longitudinally measured phenotypes in GWAS
[3,4,14,43–45]. However, most studies have only focused on single variant tests.
Regardless of the extensive discovery of the genetic common variants associated with
complex traits, the identified genetic variants explain only a fraction of total heritability
which is often termed “missing heritability”. Although many possible explanations have
been proposed, one of the most widely accepted is that the additional heritability can be
found by studying rare variants which have the minor allele frequency (MAF) of less than
5% [46]. However, single variant tests for rare variants are underpowered due to the
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extremely low MAF. In this regard, many various variant-set association tests have been
developed to aggregate multiple rare variants within a region, for example, within a gene
or a biological pathway, to increase the detection power. Among such tests, the most two
popular approaches are burden tests and the Sequence Kernel Association Test
(SKAT)[47]. Burden tests consider a weighted sum of multiple genetic variants into a
single score and are powerful when the effects of those variants in a group are
homogeneity in direction and magnitude [48]. However, when the genomic region of
interest contains signal of both directions (e.g., both risk and protective effects), burden
tests may lose power. By contrast, SKAT evaluates the variance of the genetic effects of
a group of genetic variants by adopting a statistic of quadratic form. It is more robust to
regions where variants’ effects are in opposite directions [49] and allows different
directions and magnitudes of signals. There are several omnibus tests that unify both the
burden and SKAT tests and borrow strength from both approaches, for example, the
SKAT-O[47], MiST[50], aSPU[51], SMMAT-E[52], and ACAT-O [53]. Recently, an
aggregated Cauchy association test (ACAT) has been proposed which efficiently
combines Cauchy transformed p-values. The set-based ACAT (ACAT-V) which
combines variant-level p-values has been shown to have strong power when the genetic
association signal is sparse; and the omnibus ACAT (ACAT-O) which combines multiple
set-based tests provides another strategy to combine SKAT and burden statistics.
However, all these variant-set association tests were developed for single-time-point
measures and are not directly applicable to longitudinal repeated measures. Thus, there is
a pressing need to develop powerful and efficient variant-set tests for rare variants in
longitudinal GWA studies.
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There are some attempts to fill this need. For example, Wang et al. extended the
burden and the SKAT statistics for longitudinal continuous phenotypes by introducing LBurden and L-SKAT[44]. The two tests were developed under the linear mixed model
framework that takes into account interpersonal correlation. Similarly, He et al. extended
the GEE-based SKAT test for longitudinal continuous traits[54]. However, these tests
were derived from prospective models, and therefore rely on the correct specification of
phenotype model to maintain correct type I errors. Yet for longitudinal dichotomous
traits, especially for rare diseases and conditions, efficient sampling is widely used in
which subjects are usually sampled based on their baseline measures. Prospective
analysis in which a population-based model is used overlooks the ascertainment bias and
may cause compromised statistical inference[10]. To overcome this limitation, several
retrospective association methods have been proposed to analyze ascertained case-control
studies [10,12]. Contrast to prospective analysis, retrospective approaches in which
genotypes are treated as random conditional on phenotype and covariates are robust to
phenotype model misspecification and ascertainment bias. Recently, we extended the
retrospective tests to the study of longitudinal binary traits by proposing L-BRAT (GEEbased) and RGMMAT (GLMM-based). However, both L-BRAT and RGMMAT are
single-variant test designed for common genetic variant and thus there still lacks
retrospective approaches for longitudinal variant-set association test.
Here, we propose LSRAT (Longitudinal variant-Set Retrospective Association Tests)
and RSMMAT (Retrospective variant-Set Mixed Model Association Tests), two groups
of longitudinal retrospective variant-set tests that are constructed based on the genotype
model given the phenotype and covariates. RSMMAT can be viewed as a retrospective
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version of the recently proposed variant-set mixed model association tests (SMMAT) and
the LSRAT tests are derived under the generalized estimation equation (GEE)
framework. These tests have several advantages: (1) they are robust against trait model
misspecification; (2) they are able to adjust both static and time-varying covariates; (3)
they allow for related subjects and account for population structure; and (4) they are
computationally more efficient than existing prospective approaches. Simulation studies
showed that our proposed tests are robust to the trait model misspecification and gain
power compared to SMMAT and GEE tests. We illustrated our method in the Veterans
Aging Cohort Study to evaluate the association of repeated measures of alcohol use with
rare variants.

2.3 Methods
We consider the problem of association testing between a set of variants in a genetic
region and a longitudinal trait. Suppose genotype, phenotype, and covariate data on a
sample of 𝑛𝑛 individuals are available. The genotype data consist of genotypes at the 𝑚𝑚

variants to be tested. The phenotype data consist of repeated measurements of a

continuous or binary trait. The covariates are allowed to have both static variables such as
sex and dynamic variables such as age. We let 𝑛𝑛𝑖𝑖 denote the number of phenotype

measures on individual 𝑖𝑖 and 𝑁𝑁 = ∑𝑛𝑛𝑖𝑖=1 𝑛𝑛𝑖𝑖 denote the total number of observations. For
the 𝑖𝑖th individual, let 𝑌𝑌𝑖𝑖𝑖𝑖 be the trait value, continuous or binary, and 𝑿𝑿𝑖𝑖𝑖𝑖 be the 𝑝𝑝-

dimensional covariate vector including an intercept, measured at time 𝑡𝑡𝑖𝑖𝑖𝑖 . We define 𝒀𝒀 =

(𝑌𝑌1,1 , … , 𝑌𝑌1,𝑛𝑛1 , … , 𝑌𝑌𝑛𝑛,1 , … , 𝑌𝑌𝑛𝑛,𝑛𝑛𝑛𝑛 )𝑇𝑇 , the trait vector of length 𝑁𝑁, and 𝑿𝑿 =
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(𝑋𝑋1,1 , … , 𝑋𝑋1,𝑛𝑛1 , … , 𝑋𝑋𝑛𝑛,1 , … , 𝑋𝑋𝑛𝑛,𝑛𝑛𝑛𝑛 )𝑇𝑇 , the 𝑁𝑁 × 𝑝𝑝 covariate matrix. Let 𝑮𝑮 denote the

𝑛𝑛 × 𝑚𝑚 matrix of genotypes, where 𝐺𝐺𝑖𝑖𝑖𝑖 = 0, 1, or 2 is the number of minor alleles of

individual 𝑖𝑖 at the 𝑘𝑘th variant. Here the genotype matrix 𝑮𝑮 is indexed by individual rather

than by measurement. In order to match the dimensions of 𝒀𝒀 and 𝑿𝑿, we consider a
vertically expanded genotype matrix 𝑩𝑩𝑩𝑩 that maps the genotype data 𝑮𝑮 from the

individual level to the measurement level, where 𝑩𝑩 is defined as an 𝑁𝑁 × 𝑛𝑛 design matrix

representing the measurement clustering structure, and its (𝑙𝑙, 𝑖𝑖)th entry 𝐵𝐵𝑙𝑙𝑙𝑙 is an indicator
that the 𝑙𝑙th entry of 𝒀𝒀 belongs to the measurements on individual 𝑖𝑖.

In what follows, we introduce three groups of association testing methods for

longitudinal traits: (1) GEE-based prospective association tests; (2) LSRAT
(Longitudinal variant-Set Retrospective Association Tests); and (3) RSMMAT
(Retrospective variant-Set Mixed Model Association Tests). Like the SMMAT tests [52],
the GEE-based association tests are prospective analyses in which 𝒀𝒀 is treated as random
conditional on 𝑮𝑮 and 𝑿𝑿, whereas LSRAT and RSMMAT are retrospective analyses in
which 𝑮𝑮 is treated as random conditional on 𝒀𝒀 and 𝑿𝑿.
2.3.1

Generalized Estimating Equations (GEEs)

In the GEE-based analysis, we model the mean of the phenotype distribution, given
the genotypes and covariates, as follows
𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮, 𝑿𝑿� = 𝜇𝜇𝑖𝑖𝑖𝑖 , 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜶𝜶 + 𝑮𝑮𝑇𝑇𝑖𝑖 𝜷𝜷, 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 ,

where 𝜶𝜶 is an unknown 𝑝𝑝-dimentional vector of covariate effects, 𝜷𝜷 is an unknown

𝑚𝑚-dimensional vector of genotype effects, and 𝑔𝑔( ) is a link function, for example,
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(1)

𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝜇𝜇𝑖𝑖𝑖𝑖 for continuous phenotypes, and 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = logit(𝜇𝜇𝑖𝑖𝑖𝑖 ) for binary phenotypes.
The covariance matrix of 𝒀𝒀, denoted by 𝛀𝛀, is specified as

Var(𝒀𝒀 | 𝑮𝑮, 𝑿𝑿) = 𝛀𝛀 = 𝜙𝜙𝚪𝚪1/2 𝚺𝚺𝚪𝚪1/2 ,

where 𝚪𝚪 = diag�𝑣𝑣�𝜇𝜇1,1 �, … , 𝑣𝑣�𝜇𝜇1,𝑛𝑛1 �, … , 𝑣𝑣�𝜇𝜇𝑛𝑛,1 �, … , 𝑣𝑣�𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛 �� is an 𝑁𝑁-dimentional

diagonal matrix, 𝑣𝑣( ) is the variance function, with 𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 � = 1 for continuous traits and

𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝜇𝜇𝑖𝑖𝑖𝑖 �1 − 𝜇𝜇𝑖𝑖𝑖𝑖 � for binary traits, 𝚺𝚺 is an 𝑁𝑁 × 𝑁𝑁 working correlation matrix which

may depend on some parameter 𝛿𝛿, and 𝜙𝜙 > 0 is a dispersion parameter, with 𝜙𝜙 = 𝜎𝜎 2 for

continuous phenotypes and 𝜙𝜙 = 1 for binary phenotypes. The working correlation matrix
𝚺𝚺 is allowed to be misspecified. In Model (1), the genotype effects 𝜷𝜷 are assumed to
follow a distribution with mean 𝑾𝑾𝟏𝟏𝑚𝑚 𝛽𝛽0 and covariance 𝜏𝜏𝑾𝑾𝑾𝑾, where 𝑾𝑾 =

diag(𝑤𝑤1 , … , 𝑤𝑤𝑚𝑚 ) is a fixed, prespecified 𝑚𝑚-dimentional diagonal weight matrix, 𝟏𝟏𝑚𝑚 is an

𝑚𝑚-vector of 1’s, and 𝜏𝜏 is the variance component of genotype effects. The weights

𝑤𝑤1 , … , 𝑤𝑤𝑚𝑚 specify how the genotype effects depend on particular features of the variants.

Various weighting schemes are available, such as uniform weighting, weighting based on
some function of the minor allele frequency (MAF) of the variants [49,55], and function
or annotation-based weighting.
The GEEs for the unknown parameters (𝜶𝜶, 𝜷𝜷) are constructed as
𝑼𝑼 = �

𝑼𝑼(𝜶𝜶)
𝑿𝑿𝑇𝑇 𝚫𝚫𝛀𝛀−1 (𝒀𝒀 − 𝝁𝝁)
�=�
�,
𝑼𝑼(𝜷𝜷)
(𝑩𝑩𝑩𝑩)𝑇𝑇 𝚫𝚫𝛀𝛀−1 (𝒀𝒀 − 𝝁𝝁)

where 𝚫𝚫 = diag�𝑢𝑢�𝜇𝜇1,1 �, … , 𝑢𝑢�𝜇𝜇1,𝑛𝑛1 �, … , 𝑢𝑢�𝜇𝜇𝑛𝑛,1 �, … , 𝑢𝑢�𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛 �� is an 𝑁𝑁-dimentional

diagonal matrix and 𝑢𝑢( ) is the first derivative of 𝑔𝑔−1 ( ). To detect association between
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the trait and the genetic region of interest, we test 𝐻𝐻0 : 𝜷𝜷 = 𝟎𝟎 vs. 𝐻𝐻1 : 𝜷𝜷 ≠ 𝟎𝟎. The score
function for the genotype effects 𝜷𝜷 under 𝐻𝐻0 can be written as

� 0 𝛀𝛀
� −1
� 0 ).
𝑼𝑼0 (𝜷𝜷) = 𝑼𝑼(𝜷𝜷)|𝜶𝜶�0 ,𝟎𝟎,𝛿𝛿�0 = (𝑩𝑩𝑩𝑩)𝑇𝑇 𝚫𝚫
0 (𝒀𝒀 − 𝝁𝝁

� 0 and 𝛀𝛀
� 0 are 𝝁𝝁, 𝚫𝚫 and 𝛀𝛀 evaluated at (𝜶𝜶, 𝜷𝜷, 𝛿𝛿) = �𝜶𝜶
� 0 , 𝟎𝟎, 𝛿𝛿̂0 �, where 𝜶𝜶
� 0 and 𝛿𝛿̂0
� 0 , 𝚫𝚫
Here 𝝁𝝁
are the null estimates of 𝜶𝜶 and 𝛿𝛿 under the constraint 𝜷𝜷 = 𝟎𝟎, which can be computed

iteratively between a Fisher scoring algorithm for 𝜶𝜶 and the method of moments for 𝛿𝛿
until convergence.

Hypothesis Testing: GEE-B, GEE-S, GEE-O, GEE-E, GEE-C, and GEE-A
In the GEE model of Eq. (1), our primary interest is to test the genotype effects
𝐻𝐻0 : 𝜷𝜷 = 𝟎𝟎, which is equivalent to test the null hypothesis 𝐻𝐻0 : 𝛽𝛽0 = 0 and 𝜏𝜏 = 0. If we

assume 𝜏𝜏 = 0 and test the null hypothesis 𝐻𝐻0 : 𝛽𝛽0 = 0, the GEE-based burden test GEE-B
has the form

𝑇𝑇
𝑇𝑇 𝑇𝑇 � � −1
� −1
�
� 0 )𝑇𝑇 𝛀𝛀
� 0 ).
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 = (𝒀𝒀 − 𝝁𝝁
0 𝚫𝚫 0 𝑩𝑩𝑩𝑩𝑩𝑩𝟏𝟏𝑚𝑚 𝟏𝟏𝑚𝑚 𝑾𝑾𝑮𝑮 𝑩𝑩 𝚫𝚫0 𝛀𝛀0 (𝒀𝒀 − 𝝁𝝁

(2)

Under the null hypothesis, the statistic 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 is asymptotically distributed as 𝜑𝜑𝐵𝐵 𝜒𝜒12 ,

where 𝜒𝜒12 is a chi-squared distribution with 1 df, the scalar 𝜑𝜑𝐵𝐵 = 𝟏𝟏𝑇𝑇𝑚𝑚 𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝑸𝑸𝑸𝑸𝑸𝑸𝑾𝑾𝑾𝑾𝑚𝑚

� 0 𝛀𝛀
� −1
�
� −1 �
and 𝑸𝑸 = 𝚲𝚲 − 𝚲𝚲𝑿𝑿(𝑿𝑿𝑇𝑇 𝚲𝚲𝑿𝑿)−1 𝑿𝑿𝑇𝑇 𝚲𝚲, where 𝚲𝚲 = 𝚫𝚫
0 Cov(𝒀𝒀)𝛀𝛀0 𝚫𝚫0 and the sample
� (𝒀𝒀), is estimated by (𝒀𝒀 − 𝝁𝝁
� 0 )𝑇𝑇 .
� 0 )(𝒀𝒀 − 𝝁𝝁
covariance of 𝒀𝒀, Cov

If we assume 𝛽𝛽0 = 0 and test 𝐻𝐻0 : 𝜏𝜏 = 0, the GEE-based variance component SKAT

test GEE-S has the form

𝑇𝑇 𝑇𝑇 � � −1
� −1
�
� 0 )𝑇𝑇 𝛀𝛀
� 0 ).
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆 = (𝒀𝒀 − 𝝁𝝁
0 𝚫𝚫0 𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑮𝑮 𝑩𝑩 𝚫𝚫0 𝛀𝛀0 (𝒀𝒀 − 𝝁𝝁
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(3)

2
2
Under the null hypothesis, 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆 asymptotically follows ∑𝑚𝑚
𝑘𝑘=1 𝜑𝜑𝑆𝑆𝑘𝑘 𝜒𝜒1,𝑘𝑘 , where 𝜒𝜒1,𝑘𝑘 are

independent chi-squared distributions with 1 df, and 𝜑𝜑𝑆𝑆𝑘𝑘 are the eigenvalues of the matrix

𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝑸𝑸𝑸𝑸𝑸𝑸𝑾𝑾.

Like SKAT-O, we can combine the SKAT and burden tests by considering
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑂𝑂 = 𝜋𝜋𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 + (1 − 𝜋𝜋)𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆 .

We can see that 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑂𝑂 reduces to the GEE burden test when 𝜋𝜋 = 1 and to the GEE

SKAT test when 𝜋𝜋 = 0. An optimal 𝜋𝜋 can be chosen from the data by minimizing the p
value of 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑂𝑂 , following a similar approach to the SKAT-O method[47].

An alternative joint test, similar to MiST [50] and SMMAT-E [52] that were designed

under the mixed effects models, for testing 𝐻𝐻0 : 𝛽𝛽0 = 0 and 𝜏𝜏 = 0 can be constructed as

two independent tests: (1) a test for 𝐻𝐻0 : 𝛽𝛽0 = 0 under the constraint 𝜏𝜏 = 0, and (2) a test
for 𝐻𝐻0 : 𝜏𝜏 = 0 without any constraint on 𝛽𝛽0 . The first test is the GEE burden statistic

𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 , and the second test 𝑇𝑇𝜏𝜏 can be constructed as

� −1 𝚫𝚫
� 𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝚫𝚫
� 𝛀𝛀
� −1 (𝒀𝒀 − 𝝁𝝁
�)𝑇𝑇 𝛀𝛀
�),
𝑇𝑇𝜏𝜏 = (𝒀𝒀 − 𝝁𝝁

� and 𝛀𝛀
� are 𝝁𝝁, 𝚫𝚫 and 𝛀𝛀 evaluated at (𝜶𝜶, 𝜷𝜷, 𝛿𝛿) = �𝜶𝜶
�, 𝛽𝛽�0
�, 𝑾𝑾𝟏𝟏𝑚𝑚 𝛽𝛽�0 , 𝛿𝛿̃ �. Here 𝜶𝜶
�, 𝚫𝚫
where 𝝁𝝁
and 𝛿𝛿̃ are the estimates of 𝜶𝜶, 𝛽𝛽0 and 𝛿𝛿 under a burden-type of mean model

𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮, 𝑿𝑿� = 𝜇𝜇𝑖𝑖𝑖𝑖 , 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜶𝜶 + 𝑮𝑮𝑇𝑇𝑖𝑖 𝑾𝑾𝟏𝟏𝑚𝑚 𝛽𝛽0 , 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 .

We can show that
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(4)

� −1
�
� 0 )𝑇𝑇 𝛀𝛀
𝑇𝑇𝜏𝜏 = (𝒀𝒀 − 𝝁𝝁
0 𝚫𝚫 0 𝑩𝑩𝑮𝑮𝑮𝑮 �𝐈𝐈𝑚𝑚
−1

� 𝑩𝑩𝑮𝑮𝑮𝑮𝟏𝟏𝑚𝑚 � 𝟏𝟏𝑇𝑇𝑚𝑚 𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝑷𝑷
� 𝑩𝑩𝑩𝑩𝑾𝑾� �𝐈𝐈𝑚𝑚
− 𝟏𝟏𝑚𝑚 �𝟏𝟏𝑇𝑇𝑚𝑚 𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝑷𝑷
−1

� 0 𝛀𝛀
� −1
� 𝑩𝑩𝑩𝑩𝑾𝑾𝟏𝟏𝑚𝑚 �𝟏𝟏𝑇𝑇𝑚𝑚 𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝑷𝑷
� 𝑩𝑩𝑮𝑮𝑮𝑮𝟏𝟏𝑚𝑚 � 𝟏𝟏𝑇𝑇𝑚𝑚 � 𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝚫𝚫
− 𝑾𝑾𝑮𝑮𝑇𝑇 𝑩𝑩𝑇𝑇 𝑷𝑷
0 (𝒀𝒀

� 0 ),
− 𝝁𝝁

−1 𝑇𝑇
𝑇𝑇 � � −1 �
� 0 𝛀𝛀
� −1
�
� � −1 �
� � −1 �
� = 𝚫𝚫
where 𝑷𝑷
0 𝚫𝚫0 − 𝚫𝚫 0 𝛀𝛀0 𝚫𝚫0 𝑿𝑿�𝑿𝑿 𝚫𝚫0 𝛀𝛀0 𝚫𝚫0 𝑿𝑿� 𝑿𝑿 𝚫𝚫0 𝛀𝛀0 𝚫𝚫0 .

Some assumptions: Since the true value of 𝛽𝛽0 small, we assume including the

genetic burden score in Eq. (4) doesn’t dramatically change the variance function matrix
𝚫𝚫 and 𝛀𝛀. Independence holds when the working correlation matches the true correlation.

Alternatively, one can apply ACAT approach to combine P values of individual tests.

The variant-set ACAT test can be written as
𝑚𝑚

𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐶𝐶 = � 𝑤𝑤𝑘𝑘′ 𝑓𝑓(𝑝𝑝𝑘𝑘 )
𝑘𝑘=1

where 𝑝𝑝𝑘𝑘 is the P-value of score test of the kth genetic variants; 𝑤𝑤𝑘𝑘′ =

𝑤𝑤𝑘𝑘 �𝑀𝑀𝑀𝑀𝐹𝐹𝑘𝑘 (1 − 𝑀𝑀𝑀𝑀𝐹𝐹𝑘𝑘 ) specifies the weight for the P-value which depends on the minor
allele frequency of genetic variant; 𝑓𝑓(𝑥𝑥) = 𝑡𝑡𝑡𝑡𝑡𝑡{(0.5 − 𝑥𝑥)𝜋𝜋} performs Cauchy

transformation on each of the P-values. And the omnibus ACAT test can be used to
combined the above three variant-level tests
1
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐴𝐴 = [𝑓𝑓(𝑝𝑝𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 ) + 𝑓𝑓(𝑝𝑝𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆 ) + 𝑓𝑓(𝑝𝑝𝐺𝐺𝐺𝐺𝐺𝐺−𝐶𝐶 )]
3

Both 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐶𝐶 and 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐴𝐴 P-values can be calculated via the Cauchy-distribution-based
approximation.
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In contrast to SMMAT [52] and the GEE-based association tests which are
prospective analyses based on the phenotype given the genotypes and covariates, LSRAT
and RSMMAT are retrospective analyses based on the genotypes given the phenotype
and covariates. The advantage of the retrospective approach is that the inference is robust
to misspecification of the phenotype model, i.e., the type I error of the association tests is
still properly controlled given correct specification of the null conditional mean and
variance of the genotype data, but not the phenotype model. Since LSRAT and
RSMMAT have very similar forms, for clarity, we first present the retrospective model
and the test statistics for LSRAT, and then briefly describe the RSMMAT statistics and
emphasize the differences between the two retrospective analyses.

2.3.2

LSRAT Model and test statistics

In LSRAT, we specify a retrospective mean model of the genotype
𝐸𝐸(𝑮𝑮𝑘𝑘 |𝒀𝒀, 𝑿𝑿) = 2𝑝𝑝𝑘𝑘 𝟏𝟏𝑛𝑛 + 𝛾𝛾𝑘𝑘 𝚽𝚽𝑨𝑨, 𝑘𝑘 = 1, … , 𝑚𝑚,

(5)

where 𝑮𝑮𝑘𝑘 is the genotype vector at the 𝑘𝑘th variant, 𝑝𝑝𝑘𝑘 is its MAF which is treated as an
unknown nuisance parameter, 𝛾𝛾𝑘𝑘 is an unknown parameter of interest representing the

strength and direction of association between the phenotype and the 𝑘𝑘th variant, 𝟏𝟏𝑛𝑛 is an

𝑛𝑛-vector of 1’s, 𝚽𝚽 is an 𝑛𝑛 × 𝑛𝑛 genetic relationship matrix (GRM) representing the overall
genetic similarity between individuals due to population structure, and 𝑨𝑨 is an individual� 0 𝛀𝛀
� −1
� 0 ),
level transformed phenotypic residual vector, where we let 𝑨𝑨 = 𝑩𝑩𝑇𝑇 𝚫𝚫
0 (𝒀𝒀 − 𝝁𝝁

obtained from the null GEE model 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜶𝜶, for 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 . If we let
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� = vec(𝑮𝑮) = (𝑮𝑮1𝑇𝑇 , … , 𝑮𝑮𝑇𝑇𝑚𝑚 )𝑇𝑇 be an 𝑛𝑛𝑛𝑛-dimentional vector denoting the vectorization of
𝑮𝑮
the genotype matrix 𝑮𝑮, Model (5) can be equivalently written as
� �𝒀𝒀, 𝑿𝑿� = 2𝒑𝒑 ⊗ 𝟏𝟏𝑛𝑛 + 𝜸𝜸 ⊗ 𝚽𝚽𝑨𝑨,
𝐸𝐸�𝑮𝑮

(6)

where 𝒑𝒑 = (𝑝𝑝1 , … , 𝑝𝑝𝑚𝑚 )𝑇𝑇 is a vector of the MAFs of the 𝑚𝑚 genetic variants, 𝜸𝜸 =

(𝛾𝛾1 , … , 𝛾𝛾𝑚𝑚 )𝑇𝑇 is an unknown vector of association parameters of interest, and ⊗ is
Kronecker product.

� , which can
To form LSRAT, we require the null conditional covariance matrix of 𝑮𝑮

be specified as

� �𝒀𝒀, 𝑿𝑿� = 𝚺𝚺𝐺𝐺 ⊗ 𝚽𝚽,
Var0 �𝑮𝑮

(7)

where 𝚺𝚺𝐺𝐺 = 𝑫𝑫1/2 𝑹𝑹𝑫𝑫1/2 is an 𝑚𝑚 × 𝑚𝑚 covariance matrix of the variants. Here 𝑫𝑫 =
2
) is the marginal variance of the 𝑚𝑚 genetic variants, and 𝑹𝑹 is the
diag(𝜎𝜎12 , … , 𝜎𝜎𝑚𝑚

correlation matrix that captures the linkage disequilibrium (LD) structure. In Model (6),
the genotype-phenotype association parameters 𝜸𝜸 are assumed to follow a distribution

with mean 𝑽𝑽𝟏𝟏𝑚𝑚 𝛾𝛾0 and covariance 𝜃𝜃𝑽𝑽𝑽𝑽𝑇𝑇 , where 𝑽𝑽 is a prespecified 𝑚𝑚 × 𝑚𝑚 weight matrix
and 𝜃𝜃 is the variance component of the association parameters. Note that the weight

matrix 𝑽𝑽 in the retrospective model of Eq. (6) plays a similar role as the weight matrix 𝑾𝑾

in the prospective GEE model of Eq. (1) that is allowed to depend on features of the

variants. However, we do not require 𝑽𝑽 to be a diagonal or symmetric matrix. In fact, the
connection between 𝜸𝜸 of Eq. (6) and 𝜷𝜷 of Eq. (1) is that 𝜸𝜸 = 𝚺𝚺𝐺𝐺 𝜷𝜷 when 𝜷𝜷 tends to zero.
Therefore, one choice for the weight matrix 𝑽𝑽 in the retrospective model (6) is that 𝑽𝑽 =
𝚺𝚺𝐺𝐺 𝑾𝑾. Then, the quasi-likelihood score function for 𝜸𝜸 is given by (see Supplementary
Materials S 2.1)
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𝑼𝑼(𝜸𝜸) = 𝚺𝚺𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨 − (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺−1 𝜸𝜸.
Hypothesis Testing: LSRAT-B, LSRAT-S, LSRAT-O, LSRAT-E, LSRAT-C, and
LSRAT-A
To detect association between the trait and a genetic region of interest, we test
𝐻𝐻0 : 𝜸𝜸 = 𝟎𝟎 vs. 𝐻𝐻1 : 𝜸𝜸 ≠ 𝟎𝟎 in the retrospective model for 𝑮𝑮 conditional on 𝒀𝒀 and 𝑿𝑿 given in
Eq. (6), which is equivalent to test the null hypothesis 𝐻𝐻0 : 𝛾𝛾0 = 0 and 𝜃𝜃 = 0. If we

assume 𝜃𝜃 = 0 and test 𝐻𝐻0 : 𝛾𝛾0 = 0, the LSRAT burden statistic LSRAT-B can be
constructed as

�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨,
𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐵𝐵 = 𝑼𝑼𝑇𝑇0 (𝜸𝜸)𝑽𝑽𝟏𝟏𝑚𝑚 𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝑼𝑼0 (𝜸𝜸) = 𝑨𝑨𝑇𝑇 𝑮𝑮𝚺𝚺

(8)

�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨. Under the null model, the covariance of 𝑮𝑮𝑇𝑇 𝑨𝑨 is
where 𝑼𝑼0 (𝜸𝜸) = 𝑼𝑼(𝜸𝜸)|𝜸𝜸=𝟎𝟎 = 𝚺𝚺

Cov(𝑮𝑮𝑇𝑇 𝑨𝑨) = (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺 (see Supplementary Materials S2.2 for details). Then, the
statistic 𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐵𝐵 asymptotically follows 𝜆𝜆𝐵𝐵 𝜒𝜒12 , where the scalar 𝜆𝜆𝐵𝐵 =
�𝐺𝐺−1 𝑽𝑽𝑽𝑽𝑚𝑚 and 𝜒𝜒12 is a chi-squared distribution with 1 df.
(𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺

If we assume 𝛾𝛾0 = 0 and test 𝐻𝐻0 : 𝜃𝜃 = 0, the LSRAT variance component SKAT

statistic LSRAT-S can be constructed as

�𝐺𝐺−1 𝑽𝑽𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨.
𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝑆𝑆 = 𝑼𝑼𝑇𝑇0 (𝜸𝜸)𝑽𝑽𝑽𝑽𝑇𝑇 𝑼𝑼0 (𝜸𝜸) = 𝑨𝑨𝑇𝑇 𝑮𝑮𝚺𝚺

(9)

2
2
Under the null hypothesis, 𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝑆𝑆 asymptotically follows ∑𝑚𝑚
𝑘𝑘=1 𝜆𝜆𝑆𝑆𝑘𝑘 𝜒𝜒1,𝑘𝑘 , where 𝜒𝜒1,𝑘𝑘 are

independent chi-squared distributions with 1 df, and 𝜆𝜆𝑆𝑆𝑘𝑘 are the eigenvalues of the matrix
�𝐺𝐺−1 𝑽𝑽.
(𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝑽𝑽𝑇𝑇 𝚺𝚺

The SKAT-O type of test for LSRAT can be formulated as a weighted average of the

LSRAT-B and LSRAT-S statistics, given by
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𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝑂𝑂 = 𝜋𝜋𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐵𝐵 + (1 − 𝜋𝜋)𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝑆𝑆 .

An optimal 𝜋𝜋 is obtained through a grid search by minimizing the p value of 𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝑂𝑂 .

Analogous to the GEE-E and SMMAT-E tests in which two independent tests were

constructed, we can modify the quasi-likelihood score statistics to perform a joint test of
the null hypothesis 𝐻𝐻0 : 𝛾𝛾0 = 0 and 𝜃𝜃 = 0. Specifically, we first test 𝐻𝐻0 : 𝛾𝛾0 = 0 under the
constraint 𝜃𝜃 = 0, which is the LSRAT burden statistic 𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐵𝐵 , and then test 𝐻𝐻0 : 𝜃𝜃 = 0

without any constraint on 𝛾𝛾0 . The second variance component test can be constructed
from the null retrospective burden model

� �𝒀𝒀, 𝑿𝑿� = 2𝒑𝒑 ⊗ 𝟏𝟏𝑛𝑛 + 𝑽𝑽𝟏𝟏𝑚𝑚 𝛾𝛾0 ⊗ 𝚽𝚽𝑨𝑨.
𝐸𝐸�𝑮𝑮

If we assume the mean of association effects 𝛾𝛾0 is small and including the second

(10)

� , we obtain the estimate
term in Eq. (10) does not change the conditional covariance of 𝑮𝑮

of 𝛾𝛾0 , denoted by 𝛾𝛾�0 , by solving the quasi-likelihood score equation
given by

𝑈𝑈(𝛾𝛾0 ) = (𝑽𝑽𝟏𝟏𝑚𝑚 )𝑇𝑇 [𝚺𝚺𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨 − (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 𝛾𝛾0 ] = 0,
�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨
𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
𝛾𝛾�0 = 𝑇𝑇
.
�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 )
(𝑨𝑨 𝚽𝚽𝑨𝑨)(𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺

Then, the quasi-likelihood score function for 𝜸𝜸 under Model (9) is

�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨 − (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝚺𝚺
�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 𝛾𝛾�0
𝑼𝑼𝐵𝐵 (𝜸𝜸) = 𝑼𝑼(𝜸𝜸)|𝛾𝛾�0 = 𝚺𝚺

�𝐺𝐺−1 − 𝚺𝚺
�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 �𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 �−1 𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 � 𝑮𝑮𝑇𝑇 𝑨𝑨 = 𝑷𝑷𝑮𝑮𝑇𝑇 𝑨𝑨,
= �𝚺𝚺
−1

�𝐺𝐺−1 − 𝚺𝚺
�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 �𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 𝑽𝑽𝟏𝟏𝑚𝑚 � 𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 . Finally, the variance
where 𝑷𝑷 = 𝚺𝚺
component statistic 𝑇𝑇𝜃𝜃 can be written as

𝑇𝑇𝜃𝜃 = 𝑼𝑼𝑇𝑇𝐵𝐵 (𝜸𝜸)𝑽𝑽𝑽𝑽𝑇𝑇 𝑼𝑼𝐵𝐵 (𝜸𝜸) = 𝑨𝑨𝑇𝑇 𝑮𝑮𝑮𝑮𝑮𝑮𝑽𝑽𝑇𝑇 𝑷𝑷𝑮𝑮𝑇𝑇 𝑨𝑨.
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2
Under the null hypothesis 𝐻𝐻0 : 𝜃𝜃 = 0, 𝑇𝑇𝜃𝜃 is asymptotically distributed as ∑𝑚𝑚
𝑘𝑘=1 𝜆𝜆𝜃𝜃𝑘𝑘 𝜒𝜒1,𝑘𝑘 ,

2
where 𝜒𝜒1,𝑘𝑘
are independent chi-squared distributions with 1 df, and 𝜆𝜆𝜃𝜃𝑘𝑘 are the

eigenvalues of the matrix (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝑽𝑽𝑇𝑇 𝑷𝑷𝑷𝑷. By the central limit theorem, both 𝑽𝑽𝑇𝑇 𝑷𝑷𝑮𝑮𝑇𝑇 𝑨𝑨

�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨 asymptotically follow normal distributions, and their covariance is
and 𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺
�𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑨𝑨� = (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝑽𝑽𝑇𝑇 𝑷𝑷𝑷𝑷𝟏𝟏𝑚𝑚 = 𝟎𝟎.
Cov�𝑽𝑽𝑇𝑇 𝑷𝑷𝑮𝑮𝑇𝑇 𝑨𝑨, 𝟏𝟏𝑇𝑇𝑚𝑚 𝑽𝑽𝑇𝑇 𝚺𝚺

Therefore, 𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐵𝐵 and 𝑇𝑇𝜃𝜃 are asymptotically independent. We use Fisher’s method to
combine the p values from the two tests.

Note that all the above four LSRAT statistics involve 𝑮𝑮𝑇𝑇 𝑨𝑨, the product of the column

vectors in the genotype matrix 𝑮𝑮 and the phenotypic residual vector 𝑨𝑨, where 𝑨𝑨 is

obtained from the null prospective GEE model of the phenotype. As we can alternatively
generate the phenotypic residuals based on the GLMM model of the phenotype, we
propose in the next section a group of retrospective association testing methods using the
phenotypic residuals obtained from the GLMM.
The retrospective version of variant-set ACAT test and omnibus ACAT test are
proposed as follows:
𝑚𝑚

and

𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐶𝐶 = � 𝑤𝑤𝑘𝑘′ 𝑓𝑓(𝑝𝑝𝑘𝑘𝑟𝑟 )
𝑘𝑘=1

1
𝑇𝑇𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐴𝐴 = [𝑓𝑓(𝑝𝑝𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐵𝐵 ) + 𝑓𝑓(𝑝𝑝𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝑆𝑆 ) + 𝑓𝑓(𝑝𝑝𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐶𝐶 )]
3

where 𝑝𝑝𝑘𝑘𝑟𝑟 is the L-BRAT P-value on the 𝑘𝑘 𝑡𝑡ℎ genetic variant (e.g., retrospective single-

variant test).
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2.3.3

RSMMAT Model and Test Statistics

The SMMAT tests [52] were formulated from the GLMM
𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜶𝜶 + 𝑮𝑮𝑇𝑇𝑖𝑖 𝜷𝜷 + 𝑏𝑏𝑖𝑖𝑖𝑖 , 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 ,

where 𝜇𝜇𝑖𝑖𝑖𝑖 = 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮𝒊𝒊 , 𝑿𝑿𝑖𝑖𝑖𝑖 , 𝑏𝑏𝑖𝑖𝑖𝑖 � is the mean of a response at time 𝑡𝑡𝑖𝑖𝑖𝑖 for individual 𝑖𝑖,

given his/her genotypes, covariates, and random effect, 𝜶𝜶 and 𝜷𝜷 are the same as defined
in Model (1), the vector of random effects 𝒃𝒃 = (𝑏𝑏1,1 , … , 𝑏𝑏1,𝑛𝑛1 , … , 𝑏𝑏𝑛𝑛,1 , … , 𝑏𝑏𝑛𝑛,𝑛𝑛𝑛𝑛 )𝑇𝑇 is

assumed that 𝒃𝒃 ∼ 𝑀𝑀𝑀𝑀𝑀𝑀(𝟎𝟎, ∑𝐿𝐿𝑙𝑙=1 𝜈𝜈𝑙𝑙 𝚽𝚽𝑙𝑙 ) with 𝐿𝐿 variance component parameters 𝜈𝜈𝑙𝑙 , and
correlation matrices 𝚽𝚽𝑙𝑙 . Here we allow for multiple random effects to capture the
correlation among repeated measures from longitudinal studies.

Fitting the null GLMM model 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝑿𝑿𝑇𝑇𝑖𝑖𝑖𝑖 𝜶𝜶 + 𝑏𝑏𝑖𝑖𝑖𝑖 , for 𝑖𝑖 = 1, … , 𝑛𝑛; 𝑗𝑗 = 1, … , 𝑛𝑛𝑖𝑖 , we

generate an 𝑛𝑛-dimensional vector of phenotypic residuals 𝑪𝑪 at the individual level,

�) is a vector of fitted values,
� 0 + 𝒃𝒃
� 0 )/𝜙𝜙�, where 𝝁𝝁
� 0 = 𝑔𝑔−1 (𝑿𝑿𝜶𝜶
defined by 𝑪𝑪 = 𝑩𝑩𝑇𝑇 (𝒀𝒀 − 𝝁𝝁

and 𝜙𝜙� is an estimate of the dispersion parameter 𝜙𝜙.

Different from LSRAT, the RSMMAT model specifies that
� �𝒀𝒀, 𝑿𝑿� = 2𝒑𝒑 ⊗ 𝟏𝟏𝑛𝑛 + 𝜸𝜸 ⊗ 𝚽𝚽𝑪𝑪,
𝐸𝐸�𝑮𝑮

� is the same as that in Eq. (7), then the
and the null conditional covariance matrix of 𝑮𝑮
quasi-likelihood score function for 𝜸𝜸 is written as 𝑼𝑼(𝜸𝜸) = 𝚺𝚺𝐺𝐺−1 𝑮𝑮𝑇𝑇 𝑪𝑪 − (𝑪𝑪𝑇𝑇 𝚽𝚽𝑪𝑪)𝚺𝚺𝐺𝐺−1 𝜸𝜸.

Finally, we construct the four RSMMAT statistics RSMMAT-B, RSMMAT-S,

RSMMAT-O, and RSMMAT-E by replacing the phenotypic residual vector 𝑨𝑨 in the
corresponding LSRAT tests with the GLMM-based phenotypic residual vector 𝑪𝑪;

RSMMAT-C and RSMMAT-A by replacing the GEE score tests with GLMM ones.
Their distributions can be similarly obtained.
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(11)

2.3.4

Connection between Retrospective and Prospective Tests

To assume 𝜷𝜷 has mean 𝑾𝑾𝟏𝟏𝑚𝑚 𝛽𝛽0 and variance 𝜏𝜏𝑾𝑾𝑾𝑾, it would be equivalent to assume

𝜸𝜸 has mean 𝚺𝚺𝐺𝐺 𝑾𝑾𝟏𝟏𝑚𝑚 𝛽𝛽0 and variance 𝜏𝜏𝚺𝚺𝐺𝐺 𝑾𝑾𝑾𝑾𝚺𝚺𝐺𝐺 . If we define 𝑽𝑽 = 𝚺𝚺𝐺𝐺 𝑾𝑾, 𝛾𝛾0 = 𝛽𝛽0 and

𝜃𝜃 = 𝜏𝜏, then we will have 𝑇𝑇𝐵𝐵𝑟𝑟 = 𝑇𝑇𝐵𝐵 and 𝑇𝑇𝑆𝑆𝑟𝑟 = 𝑇𝑇𝑆𝑆 . Hence, we show the connection between

retrospective burden and SKAT statistics derived from retrospective mean model and the
original burden and SKAT test statistics. Moreover, to perform retrospective burden and
SKAT testing, it is equivalent to evaluating the distribution of burden and SKAT score
statistics retrospectively.

In this section, we introduce a retrospective model, and show the connection between
prospective and retrospective statistics.

2.4 Simulation Studies
2.4.1

Simulation of Type I Error

We performed extensive simulations to examine the type I error of LSRAT-B, S, C,
O, E, A and RSMMAT-B, S, C, O, E, A, and compare their empirical power with that of
GEE and the GLMM tests. For all the simulations, we generated 10,000 chromosomes
over a 1Mb regions using a coalescent model and mimicking the LD structure, the
recombination rate, and the population history of the European population. We generated
sequence data with 100 genetic variants selected from 4kb region in each set and
1000,000 independent sets for 7,500 individuals with seven repeated measures.
For continuous traits, in each simulation replicate, we simulated the phenotype 𝑦𝑦𝑖𝑖𝑖𝑖 for

subject 𝑖𝑖’s 𝑗𝑗th observation under the null hypothesis without genetic effects from
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𝑦𝑦𝑖𝑖𝑖𝑖 = 1.0 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑗𝑗 − 1) + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 + 𝑒𝑒𝑖𝑖𝑖𝑖
𝑖𝑖 = 1, … 𝑛𝑛; 𝑗𝑗 = 1, … 7

where 𝑋𝑋1,𝑖𝑖 is a continuous time-varying covariate that is generated from independently

from a standard normal distribution; 𝑋𝑋2,𝑖𝑖𝑖𝑖 is a binary time-invariant covariate with the

probability of taking value 1 of 0.5; 𝛽𝛽𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 2.0 models time effects; 𝑎𝑎𝑖𝑖 and 𝑟𝑟𝑖𝑖𝑖𝑖 are the

individual-level time-independent and time-dependent random effects, respectively. We
assume 𝑎𝑎𝑖𝑖 ∼ 𝑁𝑁(0, 𝜎𝜎𝑎𝑎2 ) and 𝑟𝑟𝑖𝑖 = (𝑟𝑟𝑖𝑖1 , … 𝑟𝑟𝑖𝑖7 ) ∼ 𝑀𝑀𝑀𝑀𝑀𝑀(0, 𝜎𝜎𝑟𝑟2 𝑹𝑹), where 𝑹𝑹 is a 7 × 7

correlation matrix specified by the AR(1) structure with a correlation coefficient 𝜓𝜓. The
parameters for the variance components are set 𝜎𝜎𝑎𝑎2 = 𝜎𝜎𝑟𝑟2 = 𝜎𝜎𝑒𝑒2 = 0.64 and correlation
coefficient 𝜓𝜓 = 0.7.

For the binary traits, in each simulation replicate, we simulated the phenotype 𝑦𝑦𝑖𝑖𝑖𝑖 for

subject 𝑖𝑖’s 𝑗𝑗th observation under the null hypothesis without genetic effects from

logit �𝑃𝑃�𝑦𝑦𝑖𝑖𝑖𝑖 = 1�� = −2.5 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5 𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑗𝑗 − 1) + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖

where 𝛽𝛽𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 0.2 represents time effects on the probability of developing the disease.
All other parameters are the same as those in the continuous traits. We consider a

baseline ascertainment scheme for the longitudinal dichotomous trait where 3750 case
and 3750 control subjects were sampled according to their outcome values at baseline.

2.4.2

Simulation of Empirical Power

To assess the power performance of comparing set-based tests, we randomly selected
causal variants within each of the genetic regions to simulate phenotypes under the
alternatives. Specifically, we generated continuous longitudinal phenotype by
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𝑠𝑠

𝑦𝑦𝑖𝑖𝑖𝑖 = 1.0 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑗𝑗 − 1) + � 𝐺𝐺𝑖𝑖𝑖𝑖 𝛽𝛽𝑞𝑞 + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 + 𝑒𝑒𝑖𝑖𝑖𝑖
and dichotomous longitudinal measures by

𝑞𝑞=1

𝑠𝑠

logit �𝑃𝑃�𝑦𝑦𝑖𝑖𝑖𝑖 = 1�� = −2.5 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5 𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑗𝑗 − 1) + � 𝐺𝐺𝑖𝑖𝑖𝑖 𝛽𝛽𝑞𝑞 + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖
𝑞𝑞=1

where 𝐺𝐺1 , … 𝐺𝐺𝑠𝑠 are the genotypes of randomly selected causal variants 𝛽𝛽𝑞𝑞 s are the effect

sizes for the causal variants, and the other symbols are the same as defined in the
simulation for type I error.

To investigate the impact of causal proportion, effect direction and sample sizes on
the power of different tests, we vary the above factors in our power simulation studies.
The proportion of causal variants was set to be 5%, 20% and 50% which covers cases of
sparse and dense signals. The causal effect directions of positive/negative directions were
set to be 50/50%, 80%/20% and all positive to represent different mixture proportions of
protective and deleterious causal variants. The effect size (|𝛽𝛽𝑞𝑞 |s) was set to be

𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑞𝑞 |, such that variants with a smaller MAF have a large effect size, where the

𝑐𝑐 depends on the causal proportion. We examined three sample size designs: 2,500, 5,000

and 7,500. Similar to the type I error simulation, we performed baseline ascertainment for
each of the sample size designs for the longitudinal dichotomous traits. We repeated this
procedure 1,000 times to obtain P-values for the power estimation for each test.
2.4.3

Simulation Results

Table 2.1 shows the empirical type I error rates of LSRAT- B, S, C, O, E, A and
RGMMAT- B, S, C, O, E, A and their prospective GEE tests counterparts at significance
levels of 0.01, 0.001, and 0.0001 in the variant set analysis of continuous traits. All
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twenty-four tests have well-controlled type I error rates at these significance levels except
GEE-C, which has slightly conservative type I error. Table 2.2 shows the empirical type I
error rate of the above twenty-four tests in the variant set analysis of baseline ascertained
dichotomous traits at significance level of 0.01, 0.001, and 0.0001. All twenty-four tests
have well-controlled type I error rates at theses significance levels for dichotomous traits.
Table 2.1. Type I Error Estimates for Each Tests Aimed that Testing the Association Between
Randomly Selected Genetics Regions with a Continuous Longitudinal Traits. The sample size is 7,500
subjects with seven repeated measure and type I error rate under the basis of 106 replicates.
alpha = 0.01

Burden(B)
SKAT(S)

GEE-based

ACAT-V(C)
SKAT-O(O)
SMMAT-E(E)
ACAT-O(A)

Burden(B)
SKAT(S)

GLMM-based

ACAT-V(C)
SKAT-O(O)
SMMAT-E(E)
ACAT-O(A)

alpha = 0.001

alpha = 0.0001

GEE

LSRAT

GEE

LSRAT

GEE

LSRAT

1.0E-02

1.0E-02

1.0E-03

1.0E-03

1.1E-04

1.0E-04

9.0E-03

1.0E-02

9.0E-04

1.0E-03

9.0E-05

1.0E-04

8.0E-03

1.0E-02

6.0E-04

1.0E-03

6.0E-05

1.1E-04

1.0E-02

1.1E-02

1.1E-03

1.2E-03

1.1E-04

1.2E-04

9.0E-03

1.0E-02

9.0E-04

1.0E-03

1.0E-04

1.1E-04

9.0E-03

1.1E-02

8.0E-04

1.0E-03

8.0E-05

1.1E-04

GLMM

RSMMAT GLMM

RSMMAT GLMM

RSMMAT

1.0E-02

1.0E-02

1.0E-03

1.0E-03

1.0E-04

1.0E-04

1.0E-02

1.0E-02

1.0E-03

1.0E-03

9.0E-05

9.0E-05

1.0E-02

1.0E-02

1.0E-03

1.0E-03

9.0E-05

1.0E-04

1.1E-02

1.1E-02

1.2E-03

1.2E-03

1.1E-04

1.1E-04

1.0E-02

1.0E-02

1.0E-03

1.0E-03

1.1E-04

1.1E-04

1.1E-02

1.1E-02

1.1E-03

1.1E-03

9.0E-05

9.0E-05

Table 2.2. Type I Error Estimates for Each Tests Aimed that Testing the Association Between
Randomly Selected Genetics Regions with a Baseline Ascertained Dichotomous Longitudinal Traits.
The sample size is 7,500 subjects with seven repeated measure and type I error rate under the basis of 106
replicates.
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Burden(B)
SKAT(S)
ACAT-V(C)
GEE-based

SKAT-O(O)
SMMAT-E(E)
ACAT-O(A)

Burden(B)
SKAT(S)
ACAT-V(C)
GLMM-based
SKAT-O(O)
SMMAT-E(E)
ACAT-O(A)

alpha = 0.01

alpha = 0.001

alpha = 0.0001

GEE

LSRAT

GEE

LSRAT

GEE

LSRAT

1.0E-02

1.0E-02

1.0E-03

1.0E-03

9.0E-05

1.0E-04

1.0E-02

1.0E-02

1.0E-03

1.0E-03

1.0E-04

1.1E-04

1.0E-02

1.0E-02

1.0E-03

1.1E-03

8.0E-05

1.2E-04

1.1E-02

1.1E-02

1.1E-03

1.2E-03

1.3E-04

1.4E-04

1.0E-02

1.0E-02

1.0E-03

1.0E-03

1.0E-04

1.1E-04

1.0E-02

1.1E-02

1.0E-03

1.1E-03

9.0E-05

1.2E-04

GLMM

RSMMAT GLMM

RSMMAT GLMM

RSMMAT

1.0E-02

1.0E-02

9.0E-04

1.0E-03

7.0E-05

8.0E-05

1.0E-02

1.0E-02

9.0E-04

1.0E-03

8.0E-05

9.0E-05

9.0E-03

1.0E-02

9.0E-04

1.0E-03

1.1E-04

1.2E-04

1.0E-02

1.0E-02

9.0E-04

1.0E-03

9.0E-05

1.0E-04

1.0E-02

1.1E-02

1.1E-03

1.1E-03

1.3E-04

1.4E-04

9.0E-03

1.0E-02

9.0E-04

9.0E-04

9.0E-05

1.0E-04

We compare the power between LSRAT and GEE, RSMMAT and SMMAT,
respectively under a variety of simulation conditions for both continuous and
dichotomous traits. Figure 2.1 presents the empirical power of LSRAT- B, S, C, O, E, A
for testing causal variant sets evaluated at the significance level of 2.5 × 10−6 for

longitudinal continuous traits. Each LSRAT test was compared with GEE- B, S, C, O, E,
A, respectively. Figure 2.2 presents the empirical power of LSRAT tests and GEE tests
for longitudinal dichotomous traits evaluated at the same significance level. LSRAT tests
have improved power compared to their corresponding GEE tests for longitudinal
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continuous traits, especially for longitudinal dichotomous traits. Among them, LSRATV, A, O has the most substantial power gain as compared with GEE-V, A, O.

Figure 2.1. Power plots of variant-set tests(left panel) GEE-B, S, C and LSRAT-B, S, C; omnibus
tests(right panel) GEE-O, E, A and LSRAT- O, E, A for continuous longitudinal traits. Each bar
represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10 -6 of sample
size 𝑛𝑛 = 2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and 50% which were
shown by three rows of each panel. The coeﬃcients for the causal variants are 50% positive, 80% positive,
and 100% positive which corresponds to the three columns of each panel. The effect size(|𝛽𝛽𝑖𝑖 | s) of the
causal variants are set to be |𝛽𝛽𝑖𝑖 | = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, where 𝑐𝑐 was set to 0.04 for 50% causal, 0.06 for 20%
causal and 0.12 for 5% causal.
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Figure 2.2. Power plots of variant-set tests(left panel) GEE-B, S, C and LSRAT-B, S, C; omnibus
tests(right panel) GEE-O, E, A and LSRAT- O, E, A for dichotomous longitudinal traits. Each bar
represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10 -6 of sample
size 𝑛𝑛 = 2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and 50% which were
shown by three rows of each panel. The coeﬃcients for the causal variants are 50% positive, 80% positive,
and 100% positive which corresponds to the three columns of each panel. The effect size(|𝛽𝛽𝑖𝑖 | s) of the
causal variants are set to be |𝛽𝛽𝑖𝑖 | = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, where 𝑐𝑐 was set to 0.08 for 50% causal, 0.12 for 20%
causal and 0.24 for 5% causal.

Figure 2.3 and figure 2.4 present the empirical power of RSMMAT- B, S, C, O, E, A

for testing causal variant sets evaluated at the significance level of 2.5 × 10−6 for

longitudinal continuous and dichotomous traits. We compared their power with their
prospective counterparts SMMAT B, S, C, O, E, A, respectively. For longitudinal
continuous traits, because the prospective model is correctly specified, retrospective
GLMM-based tests have similar power as prospective ones. For longitudinal
dichotomous traits in which subjects were ascertained based on their baseline
observations, the prospective modeling is misspecified. In this situation, RSMMAT tests
have substantially increased power as compared with GLMM tests. The most notable
increase of power is observed comparing the aggregated Cauchy association variant-set
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test (RSMMAT-C and GLMM-C), where GLMM-C has substantially lesser power than
RSMMAT-C. This is because the aggregated Cauchy association variant-set test is based
on the P-values of each single variant test. And as was shown in the previous study[56],
the GLMM-based single variant test is underpowered in ascertained phenotypes, which
compromised the power of the aggregated test.

Figure 2.3. Power plots of variant-set tests (left panel) GLMM-B, S, C and RSMMAT-B, S, C;
omnibus tests (right panel) GLMM-O, E, A and RSMMAT- O, E, A for continuous longitudinal
traits. Each bar represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10
-6
of sample size 𝑛𝑛 = 2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and
50% which were shown by three rows of each panel. The coeﬃcients for the causal variants are 50%
positive, 80% positive, and 100% positive which corresponds to the three columns of each panel. The effect
size(|𝛽𝛽𝑖𝑖 | s) of the causal variants are set to be |𝛽𝛽𝑖𝑖 | = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 where 𝑐𝑐 was set to 0.04 for 50% causal,
0.06 for 20% causal and 0.12 for 5% causal.

67

Figure 2.4. Power plots of variant-set tests (left panel) GLMM-B, S, C and RSMMAT-B, S, C;
omnibus tests(right panel) GLMM -O, E, A and RSMMAT- O, E, A for dichotomous longitudinal
traits. Each bar represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10
-6
of sample size 𝑛𝑛 = 2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and
50% which were shown by three rows of each panel. The coeﬃcients for the causal variants are 50%
positive, 80% positive, and 100% positive which corresponds to the three columns of each panel. The effect
size(|𝛽𝛽𝑖𝑖 | s) of the causal variants are set to be |𝛽𝛽𝑖𝑖 | = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, where 𝑐𝑐 was set to 0.08 for 50%
causal, 0.12 for 20% causal and 0.24 for 5% causal.

The power increases with the sample size and decreases when the proportion of
causal signals of the same direction drops from 100% to 50% for all tests, but with the
most considerable decrease observed for burden types of tests. Among the three types of
variant-set tests, the ACAT-V tests are more powerful in the 5% causal scenario where
the causal signal is sparse but less powerful when the signal is dense (20% and 50%
causal). Burden tests are more powerful when the causal proportion is high (50%) and the
signals are in the same direction (100% positive) for a small sample size (2.5k), but the
advantage of burden tests diminishes as the sample size increases. For omnibus tests, all
three types of the omnibus tests in general show similar power and robustness to the
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direction and proportion of causal variants. SKAT-O has an advantage when the there is a
large set of causal variants (50%) while ACAT-O gains advantage when the proportion of
causal variants is small (5%). SKAT-E has slightly less powerful than SKAT-O but it is
computationally more efficient.
Comparing the performance of GEE-based tests and GLMM-based tests, the
simulation results suggest that GLMM-based tests are slightly more powerful than GEEbased tests for longitudinal continuous traits. This is due to the fact that the GLMM
model fitted has correctly specified random components whereas GEE model used AR1
correlation structure and sandwich estimator. On the other hand, GEE-based tests are
much more powerful than GLMM-based tests for longitudinal dichotomous traits with
efficient sampling. This suggests that GEE-based tests are more robust to ascertainment
sampling than GLMM-based tests. Additionally, the retrospective analysis demonstrates
more powerful gain than prospective tests in longitudinal dichotomous traits.

2.5 Application: VACS Alcohol Use GWAS Data
2.5.1

Association Analysis

To illustrate the use of our proposed tests, we analyzed a GWAS data set of alcohol
use disorder from VACS [57]. VACS is a longitudinal observational cohort study of both
HIV-positive and uninfected veterans. It has the aim of understanding the role of
psychiatric conditions including alcohol and other substance abuse in the clinical
consequences of HIV infection. Our use of the VACS data was approved by both the
Yale Human Research Protection Program and the Institutional Review Board of the
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Veterans Affairs Connecticut Healthcare System. Our data source was alcohol use
disorders identification test-consumption (AUDIT-C) questionnaire. This data is
longitudinal as the questionnaire was collected over time for six clinic visits, on a total of
2,470 patients. The AUDIT-C score is a reliable and valid measure to assess the risk of
harmful alcohol use, which has been used in previous VACS studies. The score ranges 0
to 12, where 0 reflects no alcohol use and evaluates three measures of alcohol
consumption. These measures include the frequency of usual consumption, the quantity
of usual consumption, and the frequency of binge drinking. The missing rate at each visit
ranges from 3.0% to 58.3%. The average AUDIC-C score for HIV positive subjects is
3.90 and for HIV negative subjects is 4.19.
All samples were genotyped on the Illumina OmniExpress BeadChip and were
imputed using 1000 Genome Phase 3 data as a reference panel using IMPUTE2[23]. We
performed quality-control (QC) on the subjects and the genetic variants. A detailed
description of the subject level QC process can be found in our previous study[56]. SNPs
that satisfied all of the following QC conditions were included in this analysis: (1) call
rate > 95%, (2) Hardy-Weinberg 𝜒𝜒 2 statistic P-value > 10-6. We annotated variants to

genes using ANNOVAR [58].The resulting data set has 2,210 individuals who have both
genotype and phenotype information and a total of 32,233 genes. Gender, age at baseline,
HIV status, and top five principal components (PCs) were included as static covariates
and the time of visit was included as a dynamic covariant.
We performed genome-wide association gene-based testing for the longitudinal
AUDIT-C score on 32,233 genes in a total of 2,210 subjects. We considered GEE,
LSRAT, GLMM and RSMMAT tests with adjustment for sex, baseline age, HIV status,
70

visit time and top five PCs. For each of the four types of tests (GEE, GLMM, LSRAT,
RSMMAT), we consider three variant-set tests (B, S, C) and three omnibus tests (O, E,
A). In total, we evaluated twenty-four tests. The genomic control inﬂation factors for the
twelve tests ranges from 0.92 to 1.06.
Table 2.3 summarizes genes identified by GEE model based prospective and
retrospective variant-set and omnibus tests (GEE and LSRAT) with P-values less than
5 × 10−5 in at least one longitudinal test. Table 2.4 summarizes genes identified by

GLMM model based prospective and retrospective variant-set and omnibus tests (GLMM
and RSMMAT) with P-values less than 10−4 in at least one longitudinal test. Gene

UBE2L3 was identified as a top gene from both GEE model based tests and GLMM
model based tests. This gene, encoding ubiquitin-conjugating enzyme E2, was recently
reported in another GWA study to interact with alcohol consumption and was also
significantly associated with lipid levels [59]. In a previous study, it was identified as an
ethanol‐responsive gene in the prefrontal cortex in mice[60]. This suggests that UBE2L3
could be implicated in alcoholism. Gene EFCAB10, located at 7q22.3, is another protein
coding gene that was also identified among top genes in both models. An SNP located
within this gene was formerly found in association with bipolar disorder [61], a
commonly co-occurred disorder with alcoholism [62]. Gene NPIPB3 is a protein coding
gene located at 16p12.2. This gene was reported to be associated with extremely
impulsively violence and aggressive behavior in males. As was suggested in previous
studies, the frequently observed comorbidity of alcohol use disorder and impulsive
aggression implicate a shared genetic basis underlies these two disorders [63–65]. In
another study, an intron variant (rs12923444) located in the promoter region of NPIPB3
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was found significantly associated with depression in a Genome-wide meta-analysis[66].
Our tests found gens to be significantly associated with alcohol use disorder that have
been previously shown to be associated with alcoholism or major psychiatric disorders
that comorbid with alcoholism.
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Table 2.3. Top genes with P-value < 5×10-5 in at least one of the GEE and LSRAT in the VACS
sample. * denotes protein coding gene, bold denotes the minimum P-value for the given gene. The smallest
P-value among all tests at the given genes are in bold.
Prospective
Gene

SNPs Chr

GEE-B

Retrospective

LSRAT- LSRAT- LSRAT- LSRAT- LSRAT- LSRATGEE-S GEE-C GEE-O GEE-E GEE-A B
S
C
O
E
A

MIR4454

10

4

4.49E-04 1.44E-05 4.65E-05 3.25E-05 6.95E-05 3.15E-05 1.28E-03 8.73E-05 3.32E-04 1.61E-04 3.48E-04 1.98E-04

UBE2L3*

324

22

3.52E-05 2.63E-03 1.50E-02 6.11E-05 2.43E-04 7.52E-05 1.97E-05 4.08E-04 1.02E-02 5.46E-05 1.73E-04 5.89E-05

C9orf40*

15

9

8.34E-02 7.90E-02 1.03E-03 1.30E-01 3.68E-02 4.57E-03 8.00E-02 6.81E-02 2.21E-05 1.28E-01 2.36E-02 7.70E-05

LINC01455 136

5

7.31E-02 5.55E-03 6.10E-03 1.23E-02 1.89E-02 9.14E-03 7.18E-02 2.90E-03 4.29E-05 6.22E-03 3.09E-03 1.45E-04

ZNF33A*

202

10

8.58E-02 9.30E-04 5.04E-05 2.16E-03 2.33E-03 2.54E-04 7.85E-02 4.71E-04 8.40E-04 1.09E-03 2.57E-03 9.24E-04

ZNF25*

130

10

4.17E-01 6.41E-02 5.45E-05 9.97E-02 1.31E-02 3.07E-04 3.82E-01 4.79E-02 9.66E-04 7.71E-02 1.54E-02 3.17E-03

TMEM198B 14

12

5.58E-04 3.83E-02 5.51E-02 9.62E-04 2.62E-03 1.31E-03 5.93E-05 1.06E-02 2.27E-02 1.72E-04 5.08E-04 1.87E-04

NPIPB4*

8

16

6.85E-05 8.43E-03 1.38E-02 1.41E-04 5.64E-04 1.51E-04 8.65E-05 7.45E-03 2.14E-02 1.99E-04 8.78E-04 2.70E-04

EGF*

483

4

5.86E-01 3.72E-04 6.98E-05 9.84E-04 7.40E-04 2.76E-04 6.13E-01 2.44E-04 7.82E-04 6.36E-04 5.21E-04 5.68E-04

PROX1-AS1 233

1

6.63E-01 2.68E-02 1.02E-02 5.45E-02 4.07E-02 2.69E-02 6.66E-01 2.12E-02 8.64E-05 4.19E-02 2.43E-02 2.96E-04

EFCAB10* 8

7

1.29E-01 5.20E-04 1.83E-03 1.40E-03 1.18E-03 1.21E-03 9.56E-02 8.86E-05 1.30E-04 2.47E-04 1.28E-04 1.62E-04

Table 2.4. Top genes with P-value < 10-4 in at least one of the GLMM and RSMMAT in the VACS
sample. * denotes protein coding gene, bold denotes the minimum P-value for the given gene. The smallest
P-value among all tests at the given genes are in bold.
Prospective
Gene
UBE2L3*

Retrospective

SNPs Chr

LSRAT- LSRAT- LSRAT- LSRAT- LSRAT- LSRATGEE-B GEE-S GEE-C GEE-O GEE-E GEE-A B
S
C
O
E
A

324 22

3.59E-05 1.32E-03 1.40E-02 9.44E-05 3.31E-04 1.13E-04 5.27E-05 1.09E-03 1.31E-02 1.41E-04 4.46E-04 1.58E-04

LINC01455 136 5

9.13E-02 4.66E-03 6.55E-05 9.76E-03 7.27E-03 2.48E-04 9.80E-02 4.58E-03 3.84E-05 9.66E-03 6.04E-03 1.40E-04

PROX1-AS1 233 1

6.86E-01 1.48E-02 8.44E-05 2.83E-02 1.53E-02 3.20E-04 6.81E-01 1.56E-02 4.55E-05 3.10E-02 1.83E-02 1.66E-04

LINC00467 219 1

9.58E-05 3.11E-03 1.29E-02 2.57E-04 7.81E-04 2.95E-04 6.53E-05 3.03E-03 1.21E-02 1.78E-04 5.53E-04 2.02E-04

C9orf40*

9

1.04E-01 1.00E-01 1.33E-04 1.66E-01 4.15E-02 4.98E-04 1.00E-01 1.01E-01 7.22E-05 1.64E-01 4.06E-02 2.63E-04

7

1.81E-01 1.16E-04 5.59E-04 3.14E-04 2.34E-04 2.97E-04 1.69E-01 9.19E-05 3.99E-04 2.54E-04 1.66E-04 2.24E-04

2

3.68E-02 2.98E-03 1.61E-04 5.43E-03 2.83E-04 5.65E-04 3.36E-02 2.55E-03 1.00E-04 4.60E-03 1.52E-04 3.42E-04

15

EFCAB10* 8
LOC101927
661
2
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2.5.2

Pathway and eQTL Enrichment Analysis

We performed pathway analysis on the SNPs contained in the top genes for which at
least one of the longitudinal tests had a P-value < 5 × 10−5 using METACORE. Of the

top ten significant pathways we found, four were particularly of interests. The first one is
HTR2A (alias 5-HT2A) signaling, which belongs to neurophysiological process in the
nervous system. HTR2A receptor agonist are emerging as a popular therapeutic treatment
for alcohol dependence and other neuropsychiatric conditions, and it was studied to
normalize dysregulated GABAergic signaling [67]. The second one is canonical WNT
signaling pathway, which plays a vital role in neural cell proliferation during neural
development. This pathway has been suggested by many studies to be associated with
major psychiatric disorders, including bipolar disorder and schizophrenia [68,69]. The
third and fourth pathways are adenosine A1 and adenosine A3 receptor signaling.
Adenosine plays a crucial role in regulating neural activity in the central nervous system
and it modulates many neurotransmitters. It has been found to be central to many
pathophysiological processes including drug dependence and alcohol abuse [70,71].
Overall, these four significant pathways all have been shown previously to be associated
with major psychiatric disorders and alcoholism, verifying our model is capable of
identifying biologically relevant loci.
Next, we performed an enrichment analysis to see if the top genes from our analysis
are likely to regulate brain gene expression. Previous studies have shown that genes
regulating brain tissue regulation are useful in understating the basis of psychiatric
disorders [72]. The cis-eQTLs of 13 human brain regions reported from the GTEx project
were considered in the analysis. We performed Fisher’s exact test to examine the
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enrichment of brain region eQTLs (FDR < 0.05) in the SNPs contained in the top genes
from GEE and LSRAT test. Among the brain regions, three brain regions showed
significant enrichment: anterior cingulate cortex (odds ratio = 9.40, P-val < 2.20×10-16),
cerebellar hemisphere (odds ratio = 5.53 , P-val = < 2.2×10-16), and cerebellum(odds
ratio = 3.97 , P-val < 2.20×10-16These three brain regions were also significantly
enriched in top genes identified from GLMM and RSMMAT tests: anterior cingulate
cortex (odds ratio = 4.48, P-val < 2.20×10-16), cerebellar hemisphere (odds ratio = 2.26,
P-val = 1.01×10-10) and cerebellum (odds ratio =1.76 , P-val =1.02×10-6 ).These results
show that the top genes identified from our tests are likely to regulate gene expression in
those two brain regions, which will be discussed more extensively in the discussion
section.

2.6 Discussion
We have developed and implemented LSRAT and RSMMAT, two families of
retrospective variant-set tests for longitudinally measured continuous and binary traits in
large scale genome wide association studies. In particular, LSRAT is a family of GEE
model based association tests which include three variant-set level tests: the burden test
(LSRAT-B), SKAT (LSRAT-S), and ACAT (LSRAT-C), as well as three omnibus tests
that combines burden and SKAT with different strategies: LSRAT-O, LSRAT-E, and
LSRAT-A. For comparison we also proposed RSMMAT, the mixed model counterparts
of LSRAT, which introduced retrospective analysis to the existing prospective variant-set
tests (SMMAT). Both LSRAT and RSMMAT are retrospective tests that are constructed
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based on the genotype model given the phenotype and covariates. LSRAT models the
within subject dependence with working covariance matrix whereas RSMMAT captures
it with random effects. These two families of retrospective tests for longitudinal traits
have several advantages: (1) they are robust against trait model misspeciﬁcation; (2) they
are able to adjust both static and time-varying covariates; (3) they allow for related
subjects and account for population structure; and (4) they are computationally more
efﬁcient than existing prospective approaches. They provide important tools for the study
of the genetic mechanism of longitudinal phenotypes especially for the psychiatric
disorders where the temporal course and developmental pattern of the traits are of
valuable information and has been less studied.
LSRAT also has limitations. As mentioned previously, SMMAT p values are
computed based on asymptotic distributions, which may be violated in small samples,
especially for binary traits. Additionally, the p value computed for SMMAT-E relies on
the assumption that the working correlation specified is the true correlation structure.
However, benefitting from the robustness of GEE estimators to correlation structure
model misspecification, the simulation results showed that LSRAT-E p-value maintained
a correct type I error rate even when the correlation structure is not correctly specified.
We applied LSRAT and RSMMAT to longitudinal association analysis of alcohol use
in the VACS data. Pathway analysis of the top genes identified four significant pathways
associated with longitudinal alcohol use: the HTR2A signaling pathway, the canonical
WNT signaling pathway, the adenosine A1 and adenosine A2 signaling pathways.
Enrichment analysis of brain region eQTLs demonstrated that top genes comprised of
SNPs are enriched with eQTLs from two brain regions: anterior cingulate cortex and
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cerebellum. The anterior cingulate cortex which mediates willed control of actions, was
previously found to contribute to drug addiction[73]. Recently, it was studied that the
thickness of anterior cingulate cortex is associated with alcohol use patterns [74]. As the
cerebellar dysfunction and degeneration are commonly observed in alcoholics, the
function of which has long been considered to be associated with alcoholism [75]. There
are accumulating evidence that connect cerebellum to genetic risk for developing alcohol
use disorder. In a recent study, it was demonstrated the strong influence of cerebellar in
the susceptibility to alcohol abuse and the cerebellar has been highlighted as a target for
pharmacological treatment of alcohol use disorder [76].
In summary, LSRAT and RSMMAT provide a retrospective association framework
for variant-set tests in large-scale genome-wide association for longitudinal traits. As the
electronic health records become more available, these two families of tests will serve as
powerful tools to uncover the mechanism of genes that control the developmental
trajectories of traits, especially for psychiatric traits where the progression and
developmental trajectories convey more valuable and reliable information than single
time points measures. We expect a future extension of the proposed methods towards
functional modeling of the genetic temporal effects as well as separately testing geneenvironment interaction in longitudinal GWA studies to improve the discovery process of
the genetic basis for complex traits.
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Chapter 3

Gene-graph based imputation method for
single-cell RNA sequencing data
3.1 Abstract
Single-cell RNA sequencing technology provides an opportunity to study gene
expression at single-cell resolution. However, prevalent dropout events result in high data
sparsity and noise that may obscure downstream analyses in single-cell transcriptomic
studies. We propose a novel method, G2S3, that imputes dropouts by borrowing
information from adjacent genes in a sparse gene graph learned from gene expression
profiles across cells. We applied G2S3 and ten existing imputation methods to eight
single-cell transcriptomic datasets to compare their performance. Our results
demonstrated that G2S3 is superior in recovering true expression levels, identifying cell
subtypes, reconstructing cell trajectories, identifying differentially expressed genes, and
recovering gene correlation relationships, especially for genes with relatively low
expression levels. Moreover, G2S3 is computationally efficient for imputation in largescale single-cell transcriptomic datasets.

3.2 Introduction
Singe-cell RNA sequencing (scRNA-seq) has emerged as a state-of-the-art technique
for transcriptome analysis. Compared to bulk RNA-seq that measures the average gene
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expression profile of a mixed cell population, scRNA-seq measures expression profile of
individual cells and thus describes cell-to-cell stochasticity in gene expression.
Applications of this technology in humans have revealed rare and novel cell types [77–
79], cell population composition changes [80], and cell-type specific transcriptomic
changes [79,81] that are associated with diseases. These findings have great potential to
promote our understanding of cell function, disease pathogenesis, and treatment response
for more precise therapeutic development [82,83]. However, analysis of scRNA-seq data
can be challenging due to low library size, high noise level, and prevalent dropout events
[84]. Particularly, dropouts lead to an excessive number of zeros or close to zero values
in the data, especially for genes with low or moderate expression. These inaccurately
measured gene expression levels may obscure downstream quantitative analyses such as
cell clustering and differential expression analyses [82].
In the past few years, several imputation methods have been developed to recover
dropout events in scRNA-seq data. A group of methods, including kNN-smoothing [85],
MAGIC [86], scImpute [87], drImpute [88], and VIPER [89], assess between-cell
similarity and impute dropouts in each cell using its similar cells. Specifically, kNNsmoothing uses step-wise k-nearest neighbors to aggregate information from the 𝑘𝑘 closest

neighboring cells of each cell for imputation. MAGIC constructs an affinity matrix of
cells and aggregates gene expression across similar cells via data diffusion to impute

gene expression for each cell [86]. scImpute infers dropout events based on the dropout
probability estimated from a Gamma-Gaussian mixture model and only imputes these
events by borrowing information from similar cells within cell clusters detected by
spectral clustering [87]. drImpute identifies similar cells through K-means clustering and
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performs imputation by averaging expression levels of cells within the same cluster [88].
While these imputation methods improved the quality of scRNA-seq data to some extent,
they were found to eliminate natural cell-to-cell stochasticity which is an important piece
of information available in scRNA-seq data compared to bulk RNA-seq data [89]. VIPER
overcomes this limit by considering a sparse set of neighboring cells for imputation to
preserve variation in gene expression across cells [89]. In general, imputation methods
that borrow information across similar cells tend to intensify subject variation in scRNAseq datasets with multiple subjects, which causes cells from the same subject to be more
similar than those from different subjects. To address this issue, SAVER borrows
information across similar genes instead of cells to impute gene expression using a
penalized regression model [90]. There are other methods that leverage information from
both genes and cells. For example, ALRA imputes gene expression using low-rank
matrix approximation [91], and scTSSR uses two-side sparse self-representation matrices
to capture gene-to-gene and cell-to-cell similarities for imputation [92]. In addition,
machine learning-based methods, such as autoImpute [93], DAC [94], deepImpute [95]
and SAUCIE [96], use deep neural network to impute dropout events. While
computationally more efficient, these methods were found to generate false-positive
results in differential expression analyses [97]. Recently, an ensemble approach,
EnImpute, was developed to integrate multiple imputation methods using weighted
trimmed mean [98].
In this article, we develop G2S3, a sparse and smooth signal of gene graph-based
method that imputes dropout events in scRNA-seq data by borrowing information across
similar genes. G2S3 learns a sparse graph representation of gene-gene relationships from
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the data, in which each node represents a gene and is associated with a vector of
expression levels in all cells considered as a signal on the graph. The graph is then
optimized under the assumption that signals change smoothly between connected genes.
Based on this graph, a transition matrix for a random walk is constructed so that the
transition probabilities between genes with similar expression levels across cells are
higher. A random walk on this graph imputes the expression level of each gene using the
weighted average of expression levels from itself and adjacent genes in the graph. In this
way, G2S3, like SAVER, makes use of gene-gene relationships to recover the true
expression levels. However, unlike SAVER which uses a penalized regression model for
imputation, G2S3 optimizes the gene graph structure using graph signal processing that
captures nonlinear correlations among genes and is robust to outliers in the data. The
computational complexity of the G2S3 algorithm is a polynomial of the total number of
genes in the graph, so it is computationally efficient, especially for large scRNA-seq
datasets with hundreds of thousands of cells.

3.3 Material and methods
3.3.1

G2S3 algorithm

To borrow information from similar genes for data imputation, G2S3 first builds a
sparse graph representation of gene network under the assumption that expression levels
change smoothly between closely connected genes. Let 𝑋𝑋 = [𝑥𝑥1 , 𝑥𝑥2 , … , 𝑥𝑥𝑚𝑚 ] ∈ ℝ𝑛𝑛×𝑚𝑚

denote the observed transcript counts of 𝑚𝑚 genes in 𝑛𝑛 cells, where the column 𝑥𝑥𝑗𝑗 ∈ ℝ𝑛𝑛

represents the expression vector of gene 𝑗𝑗, for 𝑗𝑗 = 1, … , 𝑚𝑚. We regard each gene 𝑗𝑗 as a
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vertex 𝑉𝑉𝑗𝑗 in a weighted gene graph 𝐺𝐺 = (𝑉𝑉, 𝐸𝐸), in which the edge between genes 𝑗𝑗 and 𝑘𝑘
is associated with a weight 𝑊𝑊𝑗𝑗𝑗𝑗 .

.
The gene graph is then determined by the weighted adjacency matrix 𝑊𝑊 ∈ ℝ𝑚𝑚×𝑚𝑚
+

G2S3 searches for a valid adjacency matrix 𝑊𝑊 from the space

𝒲𝒲 = {𝑊𝑊 ∈ ℝ𝑚𝑚×𝑚𝑚
: 𝑊𝑊 = 𝑊𝑊 𝑇𝑇 , diag(𝑊𝑊) = 0}
+

that is optimal under the assumption of smoothness and sparsity on the graph. To achieve
this, we use the objective function adapted from Kalofolias’s model [99]:
1
min ‖𝑊𝑊 ∘ 𝑍𝑍‖1,1 − 1𝑇𝑇 log(𝑊𝑊1) + ‖𝑊𝑊‖2𝐹𝐹 ,
𝑊𝑊∈𝒲𝒲
2

(1)

where 𝑍𝑍 ∈ ℝ𝑚𝑚×𝑚𝑚
is the pairwise Euclidean distance matrix of genes, defined as 𝑍𝑍𝑗𝑗𝑗𝑗 =
+
2

�𝑥𝑥𝑗𝑗 − 𝑥𝑥𝑘𝑘 � , ‖⋅‖1,1 is the elementwise L-1 norm, ∘ is the Hadamard product, and ‖⋅‖𝐹𝐹 is
the Frobenius norm. The first term in Eq. (1) is equivalent to 2 tr(𝑋𝑋 𝑇𝑇 𝐿𝐿𝐿𝐿) that quantifies
how smooth the signals are on the graph, where 𝐿𝐿 is the graph Laplacian and tr(. ) is the
trace of a matrix. This term penalizes edges between distant genes, so it prefers to put a
sparse set of edges between the nodes with a small distance in 𝑍𝑍. The second term in Eq.

(1) represents the node degree which requires the degree of each gene to be positive to
improve the overall connectivity of the gene graph. The third term in Eq. (1) controls
sparsity to penalize the formation of large edges between genes.
The optimization of Eq. (1) can be solved via primal dual techniques [100]. We rewrite
Eq. (1) as
𝑚𝑚(𝑚𝑚−1)
2

min 1{𝑤𝑤≥0} + 2𝑤𝑤 𝑇𝑇 𝑧𝑧 − 1𝑇𝑇 log(𝑑𝑑) + ‖𝑤𝑤‖2 ,

where 𝜔𝜔 = �𝑤𝑤 ∈ ℝ+

𝑤𝑤∈𝜔𝜔
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�,

(2)

where 𝑤𝑤 and 𝑧𝑧 are vector forms of 𝑊𝑊 and 𝑍𝑍, respectively, 𝑑𝑑 = 𝐾𝐾𝐾𝐾 ∈ ℝ𝑚𝑚 and 𝐾𝐾 is the
linear operator that satisfies 𝑊𝑊1 = 𝐾𝐾𝐾𝐾. After obtaining the optimal 𝑊𝑊, a lazy random walk
matrix can be constructed on the graph:

𝑀𝑀 = (𝐷𝐷−1 𝑊𝑊 + 𝐼𝐼)/2,

(3)

where 𝐷𝐷 is an 𝑚𝑚-dimensional diagonal matrix with 𝐷𝐷𝑗𝑗𝑗𝑗 = ∑𝑘𝑘 𝑊𝑊𝑗𝑗𝑗𝑗 , the degree of gene

𝑗𝑗, and 𝐼𝐼 is the identity matrix.

The imputed count matrix 𝑋𝑋imputed is then obtained by taking a 𝑡𝑡-step random walk on

the graph which can be written as

𝑇𝑇
𝑋𝑋imputed
= 𝑀𝑀𝑡𝑡 × 𝑋𝑋 𝑇𝑇 .

(4)

By default, G2S3 takes a one-step random walk (𝑡𝑡 = 1) to avoid over-smoothing. We

also implement an option of tuning the hyperparameter 𝑡𝑡 based on an objective function
that minimizes the MSE between the imputed and observed data, i.e.
𝑡𝑡 ∗ = argmin ‖𝑀𝑀𝑡𝑡 𝑋𝑋 𝑇𝑇 − 𝑋𝑋 𝑇𝑇 ‖.
𝑡𝑡

Similar to other diffusion-based methods, G2S3 spreads out counts while keeping the
sum constant in the random walk step. This results in the average value of non-zero matrix
entry decreasing after imputation. To match the observed expression at the gene level, we
rescale the values in 𝑋𝑋imputed so that the mean expression of each gene in the imputed data

matches that of the observed data. The pseudo-code for G2S3 is given in Algorithm 1.
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3.3.2

Real datasets

We evaluated and compared the performance of G2S3 and ten existing imputation
methods using datasets from eight scRNA-seq studies. Among them, four datasets were
generated using the UMI techniques and four were generated by non-UMI-based
techniques.
Reyfman refers to the scRNA-seq dataset of human lung tissue from healthy transplant
donors in Reyfman et al. [101]. The raw data include 33,694 genes and 5,437 cells. To
generate the reference dataset, we selected cells with a total number of UMIs greater than
10,000 and genes that have nonzero expression in more than 20% of cells. This ended up
with 3,918 genes and 2,457 cells.
PBMC refers to human peripheral blood mononuclear cells from a healthy donor
stained with TotalSeq-B antibodies generated by the high-throughput droplet-based system
[102].

This

dataset

was

downloaded

from

10x

Genomics

website

(https://support.10xgenomics.com/single-cell-gene-expression/datasets). The raw data
84

include 33,538 genes and 7,865 cells. To generate the reference dataset, we selected cells
with a total number of UMIs greater than 5,000 and genes that have nonzero expression in
more than 20% of cells. This ended up with 2,308 genes and 2,081 cells.
Zeisel refers to the scRNA-seq dataset of mouse cortex and hippocampus in Zeisel et
al. [103]. The raw data include 19,972 genes and 3,005 cells. To generate the reference
dataset, we selected cells with a total number of UMIs greater than 10,000 and genes that
have nonzero expression in more than 40% of cells. This ended up with 3,529 genes and
1,800 cells.
Chu refers to the dataset investigating the separation of cell subpopulations in Chu et
al. [104]. It measured gene expression of 1,018 cells including undifferentiated H1 and H9
human ES cell lines and the H1-derived progenitors. The cells were annotated with seven
cell subtypes: neuronal progenitor cells (NP), definitive endoderm cells (DE), endothelial
cells (EC), trophoblast-like cells (TB), human foreskin fibroblasts (HF), and
undifferentiated H1 and H9 human ES cells. We performed preliminary filtering to remove
genes expressed in less than 10% of cells, which resulted in 13,829 genes.
Petropoulos refers to the dataset studying cell lineage in human embryo development
in Petropoulos et al. [105]. It measured expression profiles of 26,178 genes in 1,529 cells
from 88 human embryos. Cells were labeled as E3-E7 representing their embryonic day.
We performed preliminary filtering to remove genes expressed in less than 5 cells and cells
with less than 200 expressed genes. After the filtering, we ended up with 22,934 genes and
1,529 cells.
Trapnell refers to the dataset studying the transcriptional dynamics of human
myoblasts in Trapnell et al. [106]. scRNA-seq data were collected on undifferentiated
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primary human myoblasts at time 0 and differentiating myoblasts at 24, 48 and 72 hours.
Most of the cells are mature myotubes 72 hours after inducing differentiation. The raw data
include 47,192 genes and 372 cells. We performed preliminary filtering to remove genes
expressed in less than 10% of cells, which resulted in 13,286 genes.
Paul refers to the dataset from a study on the transcriptional differentiation landscape
of myeloid progenitors [107]. This dataset includes 3,451 informative genes and 2,730 cells.
We used this dataset to evaluate the performance of imputation methods in restoring gene
regulatory relationships between well-known regulators.
Buettner refers to the dataset in Buettner et al. [108]. This dataset includes mouse ES
cells labeled by three cell cycle phases – G1, S, and G2/M via flow sorting. The raw data
include 9,571 genes and 288 cells. We used this dataset to evaluate the performance of
imputation methods in enhancing gene correlations between periodic marker genes of cell
cycle phase. We performed preliminary filtering to remove genes expressed in less than
20% of cells, which resulted in 13,355 genes.
3.3.3

Performance evaluation

Expression data recovery.
We first compared the method performance in recovering true expression levels using
down-sampled datasets. Down-sampling was performed on three independent UMI-based
scRNA-seq datasets (Reyfman, PBMC, and Zeisel) to generate benchmarking observed
datasets in a similar framework to previous studies [90,95]. In each dataset, we selected a
subset of genes and cells with high expression to be used as the reference dataset and treated
them as the true expression. Details on the thresholds chosen to generate the reference
datasets are described in the “Real datasets” section. However, unlike previous studies that
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simulated down-sampled datasets from models with certain distributional assumptions [90]
which may incur modeling bias, we performed random binary masking of UMIs in the
reference datasets to mimic the inefficient capturing of transcripts in dropout events. The
binary masking process masked out each UMI independently with a given probability. In
each reference dataset, we randomly masked out 80% of UMIs to create the down-sampled
observed dataset.
All imputation methods were applied to each down-sampled dataset to generate
imputed data separately. Because imputation methods such as SAVER and MAGIC output
the normalized library size values, we performed library size normalization on all imputed
data. We calculated the gene-wise Pearson correlation and cell-wise Spearman correlation
between the reference data and the imputed data generated by each imputation method.
The correlations were also calculated between the reference data and the observed data
without imputation to provide a baseline for comparison. To investigate whether the
performance depends on the true expression level, we stratified genes into three categories:
widely, mildly, and rarely expressed genes, based on the proportion of cells expressing
each gene in the down-sampled observed datasets. Specifically, widely expressed genes
are those with non-zero expression in more than 80% of cells, rarely expressed genes are
those with non-zero expression in less than 30% of cells, and mildly expressed genes are
those that lie in between. The gene-wise and cell-wise correlations in each stratum were
used to demonstrate the impact of expression level on the performance of imputation
methods.

Restoration of cell subtype separation.
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We applied all imputation methods to the Chu dataset to evaluate their performance in
separating different cell types. A good imputation method is expected to stabilize within
cell-subtype variation (intra-subtype distance) while maintaining between cell-subtype
variation (inter-subtype distance). Principal component analysis was conducted on the raw
and imputed data for dimension reduction. We calculated the inter-subtype distance as the
Euclidian distance between cells from different cell types, and the intra-subtype distance
as the distance between cells of the same cell type, using the top 𝐾𝐾 PCs of the data, for

𝐾𝐾 = 1, … ,50. The ratio of the average inter-subtype distance to the average intra-subtype

distance was used to quantify the performance. The higher this ratio is, the better

performance the method has. We also calculated silhouette coefficient, a composite index
reflecting both the compactness and separation of different cell types, using the top PCs
and the true cell subtype labels. The silhouette coefficient ranges from -1 to 1 with a higher
value indicating a better matching with the cell subtypes and a value close to zero indicating
random clustering [109]. To demonstrate the comparison using cell clustering results, we
visualized the raw and imputed data with UMAP plots using the top three PCs and colored
cells by the cell subtype labels. The normalized mutual information (MI) and adjusted rand
index (RI) were used to measure the consistency between cell clustering results and true
cell subtype labels. To demonstrate cell subtype separation based on cell subtype marker
genes, we further displayed DE and H1/H9 cells by plotting the log-transformed counts
using their marker genes [104]: GATA6, a marker gene of DE cells, and NANOG, a marker
gene of H1/H9 cells.

Improvement in cell trajectory inference.
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We assessed the performance of imputation methods in restoring cell trajectory using
human preimplantation embryos from different embryonic days in the Petropoulos dataset.
We considered the actual embryonic days to represent the true cell differentiation stage or
age. Monocle 2 was used to infer pseudo-time from the normalized raw and imputed data
[110]. To measure the consistency between the actual embryonic days and the
reconstructed pseudo-time, we calculated the pseudotemporal ordering score (POS) and
Kendall rank correlation coefficient (Cor). Cell trajectories were visualized by embedding
cells into two-dimensional space using reversed graph embedding, a recently developed
machine learning method to reconstruct complex single-cell trajectories [110].

Improvement in differential expression analysis.
To assess the performance in identifying differentially expressed genes, we compared
gene expression between two cell subtypes: NP and H1 cells, using both imputed scRNAseq and bulk RNA-seq data from the Chu dataset. We also compared gene expression
profiles of undifferentiated myoblasts to mature myotubes collected 72 hours after inducing
differentiation from the Trapnell dataset. The raw and imputed data were normalized and
log-transformed before evaluation. We used t-test in the bulk RNA-seq data to identify
differentially expressed genes and selected the top 200 genes as ground truth. We then
performed differential analysis in the scRNA-seq data using the same test. All the
differential expression analysis in the scRNA-seq data was performed using the Seurat R
package (version 3.0) with a default threshold to keep genes with at least 1.5-fold change.
The predictive power of differentially expressed genes identified in the raw and imputed
scRNA-seq data on the ground truth was measured by the area under an ROC curve.
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Gene correlation relationship restoration.
We finally evaluated the method performance by investigating the enhancement in gene
regulatory relationships using the Paul dataset and the recovery of gene-gene correlations
between periodic marker genes in the Buettner dataset. In the Paul dataset, we
reconstructed GRN among a set of regulators with known inhibitory and activatory
relationships in blood development [94] with the raw and imputed datasets by different
methods, using two GRN inference algorithms, GENIE3 and PPCOR. The prediction
accuracy of each method was evaluated by comparing the inferred GRN to the groundtruth network using AUPRC. The AUPRC ratio was calculated by dividing AUPRC by
that of a random predictor and the process was repeated for 50 times. The estimated
pairwise correlations between genes using the raw unimputed and imputed data by each
method were compared for performance evaluation. The Beuttner dataset contains 67
periodic marker genes with peak expression in G1/S and G2/M phases established in a
previous study [111]. As marker gene expression varies over cell cycle, we expect pairs of
periodic genes whose expression peak during the same cell cycle phase to be positively
correlated, and pairs of genes whose expression peak at different phases to be negatively
correlated. Pairwise correlations were calculated in the raw and imputed data by each
method. The proportion of gene pairs with correct direction of correlation was used to
compare the method performance.

3.4 Results
3.4.1

Evaluation overview
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We evaluated and compared the performance of G2S3 and ten existing imputation
methods, SAVER, kNN-smoothing, MAGIC, scImpute, VIPER, ALRA, scTSSR, DCA,
SAUCIE and EnImpute, in terms of (1) expression data recovery, (2) cell subtype
separation, (3) cell trajectory inference, (4) differential gene identification, and (5) gene
regulatory and correlation relationship recovery. We applied these methods to eight
scRNA-seq datasets that can be classified into five categories corresponding to the five
criteria described above. The first category includes three unique molecular identifier
(UMI)-based datasets in which down-sampling was performed to assess the method
performance in recovering true expression levels. These datasets are the Reyfman dataset
from human lung tissue [101], the peripheral blood mononuclear cell (PBMC) dataset from
human peripheral blood [102], and the Zeisel dataset from mouse cortex and hippocampus
[103]. The second category was used to evaluate the method performance in separating
different cell types. It includes the Chu dataset of human embryonic stem (ES) cell-derived
lineage-specific progenitors from seven known cell subtypes [104]. The third category was
used to reconstruct cell trajectory. It includes the Petropoulos dataset of cells from human
preimplantation embryos collected on different embryonic days [105]. The fourth category
was chosen to evaluate the method performance in identifying differentially expressed
genes. It includes the Chu dataset which is also included in the second category and the
Trapnell dataset of differentiating human myoblasts [106]. The last category includes two
datasets to evaluate the method performance in recovering gene regulatory and correlation
relationship among known regulators and marker genes. These datasets are the Paul dataset
that contains a set of well-known transcriptional regulators of myeloid progenitor
populations [107], and the Buettner dataset that contains 67 periodic marker genes whose
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expression level varies over cell cycle [108]. Table 1 summarizes the main features of all
eight datasets. A more detailed description of these datasets is provided in the “Real
datasets” section.
Table 3.1. Detailed information on the eight scRNA-seq datasets used to compare the performance of
imputation methods. * URL to access the dataset: https://support.10xgenomics.com/single-cell-geneexpression/datasets
Experiment
Category

Dataset

# Cells

Sample Type

Organism

Technique

UMI

Accession

Reyfman [23]

5,437

Lung tissue

Homo
Sapiens

Drop-seq

Yes

GEO
(GSE122960)

PBMC [24]

7,865

Peripheral blood
mononuclear cells

Homo
Sapiens

Drop-seq

Yes

10x
Genomics*

Zeisel [25]

3,005

Brain tissue

Mus
Musculus

Drop-seq

Yes

Zeisel et al.

Cell subtype
separation

Chu [26]

1,018

Embryonic stem
cells

Homo
Sapiens

Fluidigm C1

No

GEO
(GSE75748)

Cell trajectory
inference

Petropoulos
[27]

1,529

Preimplantation
embryos

Homo
Sapiens

Smart-seq2

No

Petropoulos et
al.

Chu [26]

1,018

Embryonic stem
cells

Homo
Sapiens

Fluidigm C1

No

GEO
(GSE75748)

Trapnell [28]

372

Myoblasts

Homo
Sapiens

Fluidigm C1

No

2,730

Bone marrow
myeloid
progenitor

Mus
Musculus

MARS-seq

Yes

Paul et al.

288

Staged embryonic
cells

Mus
Musculus

Fluidigm C1

No

ArrayExpress
(E-MTAB2805)

Expression
data recovery

Differential
gene
identification

Gene
correlation
relationship
recovery

3.4.2

Paul [29]

Buettner [30]

GEO
(GSE52529)

Hyperparameter tuning in G2S3

The G2S3 algorithm used graph signal processing to learn a gene graph and performed
a 𝑡𝑡-step random walk to borrow information from neighboring genes for imputation. The
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optimal value of the hyperparameter 𝑡𝑡 was selected by minimizing the mean squared error
(MSE) between the imputed and observed data, which was also used in a previous study
on diffusion-based imputation method [112]. We performed down-sampling on each
dataset from the first category (Reyfman, PBMC and Zeisel) and evaluated the MSE as
well as the gene-wise and cell-wise correlations of the G2S3 imputed data with reference
data, for 𝑡𝑡 = 1, … ,10. Fig S3.1 shows the coefficient of variation (CV) of gene expression
before and after down-sampling. In all datasets, although the CV of gene expression
increased slightly after down-sampling, the correlation between the CV before and after
down-sampling was 0.79 or higher, demonstrating that the down-sampled data well
preserved the mean-variance relationship in the reference data. Fig S3.2A shows that the
optimal value of 𝑡𝑡 is 1 in all three datasets based on the minimization of MSE. In addition,
the one-step random walk in G2S3 achieved the greatest gene-wise and cell-wise
correlations with the reference data (Fig S3.2B). This optimal choice of 𝑡𝑡 was consistent
with the hyperparameter selected by another diffusion-based imputation method [112].

3.4.3

Expression data recovery in down-sampled datasets

We conducted down-sampling on datasets from the first category (Reyfman, PBMC
and Zeisel) to assess the performance of all eleven imputation methods in recovering true
expression levels. Fig S3.1 shows the coefficient of variation (CV) of gene expression
before and after down-sampling. In all datasets, although the CV of gene expression
increased slightly after down-sampling, the correlation between the CV before and after
down-sampling was 0.79 or higher, demonstrating that the down-sampled data well
preserved the mean-variance relationship in the reference data. Fig 3.1 shows the gene93

wise Pearson correlation and cell-wise Spearman correlation between the imputed and
reference data from each dataset. The correlation between the observed data without
imputation and reference data was set as a benchmark. In all datasets, G2S3 consistently
achieved the highest correlation with the reference data at both gene and cell levels, and
SAVER and scTSSR had slightly worse performance. EnImpute had comparable
performance to G2S3 based on the cell-wise correlation but performed worse than G2S3,
SAVER and scTSSR based on the gene-wise correlation. VIPER performed well in the
Reyfman and PBMC datasets but not in the Zeisel dataset based on the gene-wise
correlation, although the cell-wise correlations were much lower than G2S3, SAVER,
scTSSR and EnImpute in all datasets. The other methods, kNN-smoothing, MAGIC,
scImpute, ALRA and DCA, did not have comparable performance, especially based on the
gene-wise correlation. SAUCIE did not have comparable performance to the other methods
in all datasets (Fig S3.2). Since genes with higher expression tend to have a lower dropout
rate, they are usually easier to impute and have less imputation need than those with lower
expression [84]. To demonstrate the impact of expression level on the method performance,
we stratified genes into three subsets based on the proportion of cells expressing them in
the down-sampled data: widely expressed (>80%, n = 155, 111, 110, respectively), mildly
expressed (30%-80%, n = 615, 357, 1,902, respectively), and rarely expressed (<30%, n =
3,148, 1,830, 1,617, respectively). Fig S3.3 shows the gene-wise and cell-wise correlations
in each gene stratum. We can see that G2S3 improved both gene-wise and cell-wise
correlations compared to the observed data for widely and mildly expressed genes.
Moreover, G2S3 achieved the most superior recovery accuracy than the other methods for
both widely and mildly expressed genes, although SAVER, scTSSR and EnImpute had
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comparable accuracy for widely expressed genes, suggesting the advantage of borrowing
information from similar genes over from similar cells. For rarely expressed genes, all
imputation methods did not improve the correlations compared to the observed data using
both gene-wise and cell-wise correlation, suggesting that there is insufficient information
for these genes to be successfully imputed. Overall, G2S3 provided the most accurate
recovery of true expression levels.

Figure 3.1. Evaluation of expression data recovery of G2S3 by down-sampling. Performance of
imputation methods measured by correlation with reference data from the first category of datasets, using
gene-wise (top) and cell-wise (bottom) correlation. Box plots show the median (center line), interquartile
range (hinges), and 1.5 times the interquartile (whiskers). Outlier data beyond this range are not shown.
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3.4.4

Restoration of cell subtype separation

The second category of datasets was used to assess the performance of imputation
methods in restoring separation between different cell types. In the Chu dataset, there were
7 cell types including two undifferentiated human ES cell lines (H1 and H9), human
foreskin fibroblasts (HF), neuronal progenitor cells (NP), definitive endoderm cells (DE),
endothelial cells (EC), and trophoblast-like cells (TB). To quantify the performance in
separating these cell subtypes, we calculated the ratio of average inter-subtype distance to
average intra-subtype distance using the top 𝐾𝐾 principal components (PCs) of the data
before and after imputation, for 𝐾𝐾 = 1, … ,50. We also calculated the silhouette coefficient

that measures how similar cells are to cells from the same cell type compared to other cell
types. In Fig 3.2, G2S3 and EnImpute had the highest inter/intra-subtype distance ratio and

silhouette coefficient. Both methods performed better than the raw unimputed data, while
MAGIC, scImpute, ALRA and DCA performed worse than the raw data. SAUCIE
performed the worst. These results suggest that G2S3 greatly improved the separation
between different cell types by enhancing the biologically meaningful information in the
top PCs. Its performance is comparable to EnImpute that takes advantage over several
methods.
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Figure 3.2. Evaluation of G2S3 in improving cell subtype separation. Average inter/intra-subtype
distance ratio (top) and silhouette coefficient (bottom) to demonstrate cell subtype separation using the top
principal components of the raw unimputed and imputed data by each method in the Chu dataset.

To demonstrate the comparison using cell clustering results, we generated uniform
manifold approximation and projection (UMAP) plots in which cells were colored to
represent the seven cell types in the original dataset. The normalized mutual information
(MI) and adjusted rand index (RI) were calculated to measure the consistency between cell
clustering results and true cell subtype labels. Fig 3.3 shows that the imputed data by G2S3
and EnImpute had a better separation of all cell subtypes than the raw unimputed data,
except for H1 and H9 cells. Given that both H1 and H9 are undifferentiated human ES cell
lines, it is expected that separating them is more difficult due to the relative homogeneity
of human ES cells compared to the progenitors. In contrast, the other imputation methods
did not have comparable improvement or even reduced the separation of different cell types.
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Specifically, DE cells were mixed with EC and TB cells in the raw data and were not
separated from the other cell subtypes by all methods except G2S3 and EnImpute. MAGIC
was able to separate EC, HF and TB cells from each other and the rest of the cell subtypes,
while SAVER was able to separate EC and HF cells from each other and the rest of the cell
subtypes. VIPER, ALRA, scTSSR and DCA only separated HF cells from the rest, similar
to the raw data. The imputed data by kNN-smoothing formed many small clusters.
scImpute tended to mix different cell types into one cluster. SAUCIE overly smoothed the
data and was not able to separate any cell types. Based on the two measures of consistency
between cell clustering results and true cell subtype labels, EnImpute had the best
separation of the cell subtypes (MI=0.77, RI=0.70) and G2S3 was the second best
(MI=0.74, RI=0.64), while the other methods did not have comparable performance.
Notice that EnImpute is an ensemble method that combines imputation results from
multiple methods, and G2S3 is the only method that achieved comparable performance to
EnImpute.

Figure 3.3. Plots showing 2D-Visualization of the Chu dataset. UMAP plots of the raw unimputed and
imputed data by all methods. Cells are colored by true cell subtype labels. The normalized mutual
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information (MI) and adjusted rand index (RI) are calculated to measure the consistency between cell
clustering results and true cell subtype labels.

Fig S3.5 demonstrates the expression of two cell subtype marker genes GATA6, a
marker gene of DE cells, and NANOG, a marker gene of H1/H9 cells [104] across all cells
in the raw unimputed and imputed data by all methods. The normalized MI and adjusted
RI that measure the consistency between cell clustering results based on these two marker
genes and true cell labels for DE and H1/H9 cells were also calculated. We can see that
G2S3 provided the best separation between H1/H9 cells, DE cells and other cell subtypes.
Specifically, while the raw data mixed H1/H9 cells with other cell subtypes, G2S3
successfully recovered the expression of GATA6 and NANOG to better separate DE and
H1/H9 cell subtypes both from each other and from the other cell subtypes. The cell
clustering results on the G2S3 imputed data achieved the highest consistency with true cell
subtype labels, indicating its best performance. None of the other methods had comparable
performance. DCA separated H1/H9 cells but had DE cells marginally overlapped with
other cell types. We observed many small clusters of cells after imputation by kNNsmoothing, similar to the pattern displayed in Fig 3.3. The other methods did not improve
cell subtype separation compared to the raw data. In addition, the imputed data by VIPER,
kNN-smoothing and ALRA still had a large proportion of dropout events. These results
suggest that G2S3 had the best performance in restoring the separation of different cell
types, preserving biological meaningful variations, and reducing technical noises.

3.4.5

Improvement in cell trajectory inference
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Reconstruction of cell trajectories using scRNA-seq data is important for investigating
a dynamic process. However, dropout events may impair pseudo-time inference. We used
the Petropoulos dataset to evaluate the performance of all imputation methods in cell
trajectory inference. This dataset consists of human preimplantation embryonic cells from
five embryonic days (E3-E7) that represent the differentiation stage or age of the
embryonic cells. We used Monocle 2 to infer pseudo-time from the raw unimputed and
imputed data by each method [110], and compared to the actual embryonic days of the cells
for performance evaluation. The pseudotemporal ordering score (POS) and Kendall rank
correlation coefficient (Cor) were calculated to measure the consistency. Fig 3.4 shows cell
trajectories in the raw and imputed data by all methods. The cell trajectory plots showed
the sequential layout of cells from earlier to later embryonic days. The imputed data by
G2S3, scImpute, VIPER and EnImpute had the highest consistency with the actual
embryonic days, indicating their best performance among all methods. SAVER, kNNsmoothing, MAGIC, ALRA and DCA formed the second tier of methods with lower
consistency. scTSSR performed worse than the raw data. SAUCIE had significantly lower
consistency (POS=0.07, Cor=0.07) compared to all other methods in cell trajectory
inference. Furthermore, the trajectory analysis showed an increased heterogeneity among
cells from later embryonic days, especially starting from embryonic day 5. This was
consistent with the observation of a significant embryonic cell differentiation event on
embryonic day 5 [105].
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Figure 3.4. Visualization of cell trajectories in the raw and imputed data by all methods. Cells are projected into
two-dimensional space using reversed graph embedding. Pseudotemporal ordering score (POS) and Kendall rank
correlation coefficient (Cor) are used to measure the consistency between the actual

3.4.6

Improvement in differential expression analysis

One common analytical task for scRNA-seq studies is to identify genes differentially
expressed between cells from two groups of subjects or two cell types. In this section, we
used two datasets to evaluate and compare the improvement in downstream differential
expression analysis before and after imputation by all methods: the Chu dataset of different
cell types and the Trapnell dataset of differentiating human myoblasts. Besides the scRNAseq data, both datasets provide bulk RNA-seq data on the same samples. The differentially
expressed genes identified from the bulk RNA-seq data were treated as ground truth. We
assessed the predictive power of the scRNA-seq data imputed by different methods on the
ground truth using receiver operating characteristic (ROC) curves.
In the Chu dataset, we identified marker genes that differentiate the two cell types: NP
and H1 cells. Fig 3.5A shows that G2S3 had the highest area under the curve (AUC) in
detecting differentially expressed genes. kNN-smoothing, DCA and EnImpute had an AUC
score lower than G2S3 but higher than the raw data. The other methods had comparable
performance to the raw data except MAGIC, which had the lowest AUC. This is likely due
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to the fact that a small cluster of NP cells were mixed with H1 cells after imputation by
MAGIC (Fig 3.3), resulting in compromised performance in marker gene identification.
Our results were largely consistent with a previous evaluation of imputation methods in
identifying differentially expressed genes using Fluidigm C1 data [113]. No genes
achieved significance in the imputed data by SAUCIE so the result of SAUCIE could not
be shown. In the Trapnell dataset, we performed differential expression analysis between
undifferentiated primary human myoblasts and mature myotubes captured 72 hours after
inducing differentiation. Fig 3.5B shows that G2S3 achieved the highest AUC indicating
its best performance, followed by VIPER. kNN-smoothing and DCA had much worse
performance than the raw data. No genes achieved significance in the imputed data by
MAGIC and SAUCIE so their results could not be shown. Altogether, the results from both
datasets showed that G2S3 had the best improvement in the downstream differential
expression analysis.

Figure 3.5. Receiver operating characteristic (ROC) curves demonstrating improvement in
differential expression analysis. ROC curves of the scRNA-seq differential expression results predicting
differentially expressed genes identified in the bulk RNA-seq data on the same samples in the Chu (A) and
Trapnell (B) datasets.
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3.4.7

Gene correlation relationship recovery

We compared the method performance in recovering gene correlation relationships
using two scRNA-seq dastasets. In the Paul dataset, we examined the pairwise correlation
between well-known transcription factors in the development of blood cells before and
after imputation [111]. In the Buettner dataset, we investigated the relationships among a
set of 67 periodic marker genes before and after imputation, in which 16 genes have peak
expression in the G1/S phase and 51 genes have peak expression in the G2/M phase [108].
In the Paul dataset, the regulatory relationship among key regulators of the
transcriptional

differentiation

of

megakaryocyte/erythrocyte

progenitors

and

granulocyte/macrophage progenitors in the raw data and the imputed data by each method
were used for performance evaluation. The gene regulatory network (GRN) of these
regulators was established in a previous study based on biological experiments [114–116]
and served as the ground truth. We reconstructed GRNs by two methods, GENIE3 [117]
and PPCOR [118], in the raw and imputed datasets. The inferred GRNs were compared to
the ground-truth network using the area under the precision-recall curve (AUPRC). For
each imputation method, we reported the AUPRC ratio (AUPRC divided by that of a
random predictor) with 50 replications. Fig 3.6 demonstrates that G2S3 achieved the
highest AUPRC ratio, followed by kNN-smoothing, using both GRN inference methods.
The AUPRC ratios of GRNs inferred from the imputed data by either MAGIC or SAUCIE
were much lower than that from a random predictor, suggesting that the gene regulatory
relationships were distorted after imputation.
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Figure 3.6. Performance of G2S3 in recovering gene regulatory relationship. Boxplots showing the
area under the precision-recall curve (AUPRC) ratios that measure the accuracy of inferred GRNs using the
imputed data by different imputation methods. Both GENIE3 (top) and PPCOR (bottom) were used to infer
GRNs. Red line indicates the performance of a random predictor.

We also examined the pairwise correlations between these key regulators. Based on
previous studies [114–116], inhibitory and activatory gene pairs were defined, among
which inhibitory pairs were expected to have negative correlation while activatory pairs
were expected to have positive correlation. The mutually inhibitory pairs of genes include
Fli1 vs. Klf1, Egr1 vs. Gfi1, Cebpa vs. Gata1, and Sfpi1 vs. Gata1; and the mutually
activatory pairs include Sfpi1 vs. Cebpa, Zfpm1 vs. Gata1, Klf1 vs. Gata1. Fig S3.6 shows
that most of the methods were able to enhance the pairwise correlations after imputation in
the correct direction. Overall, G2S3 and SAVER showed the greatest enhancement of
pairwise correlation for both inhibitory and activatory pairs, followed by kNN-smoothing
and EnImpute. Although MAGIC intensified the pairwise correlations, most activatory
pairs had correlations close to 1 after imputation. ALRA and DCA strengthened the
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pairwise correlation for activatory pairs but did not improve much for inhibitory pairs.
Imputation by SAUCIE resulted in all gene pairs to be highly positively correlated.
In the Buettner dataset, we expect pairs of periodic genes whose expression peak in the
same phase of cell cycle to be positively correlated and those that peak during different
phases to be negatively correlated. There are 67 marker genes for G1/S and G2/M phases
[111]. We examined the correlation of all 2,211 marker gene pairs in the raw data and
imputed data by each method. The proportion of gene pairs whose correlations are in the
correct direction was used for performance comparison. Table 3.2 shows that all methods
had comparable performance in maintaining a high proportion of positively correlated gene
pairs, whereas their performance varies in restoring negatively correlated gene pairs. G2S3,
SAVER and EnImpute were able to recover 28% or more of the negatively correlated gene
pairs. All gene pairs became positively correlated after imputation by MAGIC, scImpute,
VIPER, ALRA, DCA and SAUCIE, thus no negative correlation was observed after
imputation. Similar observations were found in a previous study in which some of these
methods introduced a large number of positive gene correlations after imputation, many of
which may be spurious [90].
Table 3.2. Fraction of periodic gene pairs with correct direction of correlation in the raw and
imputed data by each method

Imputation Methods
Raw
G2S3
SAVER
kNN-smoothing
MAGIC
scImpute
VIPER
ALRA

Positive Pairs
1.00
0.91
0.94
0.97
1.00
1.00
1.00
1.00
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Negative Pairs
0.00
0.32
0.28
0.17
0.00
0.00
0.00
0.00

scTSSR
DCA
SAUCIE
EnImpute

0.98
1.00
1.00
0.91

0.11
0.00
0.00
0.46

In summary, the results from both datasets suggested that G2S3 enhanced gene-gene
relationships especially for negatively correlated gene pairs in which the expression of one
gene is inhibited by the other. As lowly expressed genes are in general harder to impute,
negatively correlated relationship is a harder task for imputation to restore the correlated
relationship.
3.4.8

Summary of method performance

We evaluated and compared the performance of G2S3 and the other ten imputation
methods using five evaluation criteria corresponding to five downstream analyses of
scRNA-seq data. Fig 3.7 summarizes the overall performance of all methods. G2S3 was
ranked first in three out of the five evaluation criteria, second in cell clustering, and third
in cell trajectory inference. For those criteria under which G2S3 did not achieve the best
performance, it had close or comparable performance to the best method. No other method
achieved the best performance in as many criteria as that of G2S3. Overall, G2S3
performed the best among all the methods, followed by EnImpute and VIPER.
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Figure 3.7. Summary of performance of G2S3 and other imputation methods. A heatmap
demonstrating the method performance based on the five evaluation criteria. The left five columns display
performance rank using each of the five evaluation criteria. The rightmost column displays the overall
performance rank based on the sum of all five ranks.

3.4.9

Computation time

While SAVER and EnImpute have comparable performance to G2S3 in some datasets,
G2S3 is computationally more efficient (Table 3.3). Since both G2S3 and SAVER are gene
network-based imputation methods, their computation time is expected to increase with the
number of genes to be imputed. This makes gene network-based methods more suitable
than those based on cell similarity for large scRNA-seq datasets with tens or even hundreds
of thousands of cells. In real data analysis, G2S3 was on average about twenty times faster
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than SAVER. EnImpute is an ensemble method that relies on imputation results from
multiple methods and therefore takes longer time than SAVER. On the other hand, the
computation time of imputation methods that borrow information from similar cells
increases dramatically with the number of cells in the data. As demonstrated in a previous
study, scImpute and VIPER were unable to scale beyond 10K cells within 24 hours [95].
In our assessment, VIPER takes about two days to impute the down-sampled datasets with
several thousands of genes while other methods finish within several minutes.
Table 3.3. Computational Time for Each Imputation Methods. Running time in minutes for each
imputation task among imputation methods using a single processor on an 8-core, 50 GB RAM, Intel Xeon
2.6 GHz CPU machine. *Derived computing time sum over five methods and ensemble computing time.
G2S3

kNNscImput
SAVER smoothi MAGIC
VIPER ALRA scTSSR DCA
e
ng

SAUCI EnImpu
E
te*

Reyfman

4.27

60.12

0.25

0.35

29.46

5289.17 0.16

9.80

5.40

0.86

102.23

Zeisel

2.99

43.26

0.18

0.24

70.67

3618.86 0.10

4.26

4.27

0.74

121.84

PBMC

1.09

25.91

0.15

0.17

17.77

524.37

3.48

2.78

0.98

50.84

0.08

3.5 Discussion
We have developed a novel method G2S3 to impute dropouts in scRNA-seq data. G2S3
learns a sparse and smooth signals of gene graph from scRNA-seq data and borrows
information from nearby genes in the graph for imputation. We evaluated and compared
the performance of G2S3 and ten existing imputation methods in terms of recovering true
expression levels, restoring cell subtype separation, reconstructing cell trajectory,
identifying differentially expressed genes, and restoring gene correlation relationships
using eight scRNA-seq datasets. The results demonstrated that G2S3 achieved superior
performance or had comparable performance to other methods based on the five evaluation
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criteria above, especially for genes with relatively low expression. Furthermore, G2S3 is
the most computationally efficient method for large-scale scRNA-seq data imputation.
Unlike imputation methods that borrow information across similar cells, G2S3
harnesses the structural relationship among genes obtained through graph signal processing
to perform imputation. Using eight real datasets, we showed that methods relying on cell
similarity tend to remove biological variation among cells and intensify subject-level batch
effects. In contrast, G2S3 enhances cell subtype separation and thus relatively reduces
variations in cells from the same cell type and subject. The down-sampling and differential
expression analysis results showed that G2S3 outperformed the other methods, especially
for lowly expressed genes. Of note, imputation methods such as SAVER, scImpute and
VIPER, used parametric models for gene expression. However, as the noise distribution
varies across different scRNA-seq platforms, assumptions of the parametric models may
be violated, particularly for new technologies. Graph signal processing extracts signals
from data by optimizing a smoothness regulated objective function, so it is in principle less
sensitive to the noise distribution. To our knowledge, there are two imputation methods
that use gene graph/network for imputation in scRNA-seq data, published during the
preparation of this manuscript: netNMF-sc [119] uses network-regularized non-negative
matrix factorization to leverage gene-gene interactions for imputation; and netSmooth [120]
incorporates protein-protein interaction networks to smooth gene expression values. Both
methods require prior information on gene-gene interactions from RNA-seq or microarray
studies of bulk tissue. In contrast, G2S3 learns gene network structure in an unbiased way
from scRNA-seq data. In our experiments, G2S3 had comparable performance to EnImpute,
an ensemble learning method that combines results from multiple imputation methods.
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G2S3 learns gene-gene relationship by optimizing a sparse gene graph and at the same
time allows expression levels to change smoothly between closely connected genes. Since
many gene networks and biochemical networks are sparse [110,121,122], the sparsity
property is important for inferring gene network. There are several methods available for
constructing gene network, many of them are kernel-based, which result in full weight
matrices where sparsity has to be imposed afterwards, for example, thresholding the
adjacency weights. We found that top eigenvectors of graph Laplacian on the gene
networks learned from Gaussian kernel were highly correlated with dropout rate,
suggesting that dropout events tend to bias the construction of gene network in scRNA-seq
data. G2S3 algorithm uses one step random walk to avoid over-smoothing because multiple
steps of the random walk tended to overly smooth data and leaded to worse performance.
Similar observations were reported in another manuscript discussing parameter tuning for
diffusion-based imputation methods for scRNA-seq data [112]. It showed that for many
diffusion-based methods including MAGIC, single step (t=1) yielded better performance
than multiple steps or iterations until convergence. For UMI-based datasets, to account for
the effect of varying sequencing depths, we recommend normalizing UMI counts before
applying G2S3 for more accurate construction of gene graph and imputation of expression
levels.
Despite the advantages of G2S3 over the other imputation methods shown in this article,
G2S3 can be improved in several directions. First, G2S3 uses a lazy random walk on the
gene graph to recover dropout events, i.e., weighted average of the observed expression of
the gene of interest and that from neighboring genes. The weights currently depend only
on between gene similarity which can be improved by considering the reliability of
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observed read counts, cell library size, and dispersion of gene expression, similar to the
weights used in SAVER. Second, G2S3 does not consider dropout rate and therefore
imputes all values at once. This can be improved by calculating the probability of being a
dropout for each observed read count and only performing imputation on those with a high
dropout probability. Third, the G2S3 model can be improved by adding two tuning
parameters for the second and third terms in the objective function that control the degree
of smoothness and sparsity of the resulting gene network. The tuning parameters can be
chosen based on the complexity and structure of scRNA-seq data. Finally, G2S3 does not
consider the potential subject effect in the data, which has been shown to be prevalent and
dominant in certain cell types. One way to address this issue is to consider subject effect
as “batch” effect and remove it using batch effect removal tools. This is effective only
when there are no other effects of interest confounding the subject effect, for example,
disease effect, because they will also be removed together with “batch” effect. When there
are other effects that confound with subject effect and are the interest of study, G2S3 can
be improved to consider subject effect and disease effect at the same time in imputation.
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Supplementary Materials
Supplementary methods
S 2.1 Quasi-likelihood score of 𝜸𝜸

The quasi-likelihood score function for 𝜸𝜸 can be written as
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S 2.2 Covariance of 𝑮𝑮𝑇𝑇 𝑨𝑨

� � = (𝐈𝐈𝑚𝑚 ⊗ 𝑨𝑨)𝑇𝑇 (𝚺𝚺𝐺𝐺 ⊗ 𝚽𝚽)(𝐈𝐈𝑚𝑚 ⊗ 𝑨𝑨)
Cov(𝑮𝑮𝑇𝑇 𝑨𝑨) = Cov�(𝐈𝐈𝑚𝑚 ⊗ 𝑨𝑨)𝑇𝑇 𝑮𝑮
= 𝚺𝚺𝐺𝐺 ⊗ (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨) = (𝑨𝑨𝑇𝑇 𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺

Supplementary Figures
Figure S3.1 Comparison of the mean-variance relationship in gene expression before and after downsampling. For each gene, the coefficient of variation (CV) across all cells after down-sampling (y-axis) is
plotted against the CV of non-zero cells in the reference data (x-axis).
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Figure S3.2 Optimal value of hyperparameter in G2S3. A. Mean squared error (MSE) at different
diffusion steps in three down-sampled datasets. B. Gene-wise and cell-wise correlations of G2S3 imputed
data at different diffusion steps and the reference data.

Figure S3.3 Evaluation of expression data recovery of all imputation methods by down-sampling.
Performance of imputation methods measured by correlation with reference data from the first category of
datasets, using gene-wise (top) and cell-wise (bottom) correlation. Box plots show the median (center line),
interquartile range (hinges), and 1.5 times the interquartile (whiskers). Outlier data beyond this range are
not shown.
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Figure S3.4 Evaluation of expression data recovery of all imputation methods by down-sampling in
three gene strata. Performance of imputation methods measured by correlation with reference data from
the first category of datasets, using gene-wise (top) and cell-wise (bottom) correlation. Genes are stratified
into three groups: widely (>80%, left), mildly (30%-80%, middle), and rarely (<30%, right) expressed.

Figure S3.5 Cell subtype marker gene expression in the Chu dataset. Scatter plot showing expression
level of marker genes for DE cells (GATA6) and H1/H9 cells (NANOG). Cells are colored by the cell
subtype labels.
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Figure S3.6 Evaluation of recovering gene correlation relationship of all imputation methods in the
Paul dataset. Heatmaps of pairwise correlations between well-known blood regulators.
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